The C9orf72 GGGGCC Repeat Is Translated into A in FTLD/ALS

Science

339, 1335-1338

DOI: 10.1126/science.1232927

Citation Report

#	Article	IF	Citations
1	Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation. Molecular Neurodegeneration, 2013, 8, 12.	4.4	52
2	Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathologica, 2013, 126, 385-399.	3.9	289
3	c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. Expert Opinion on Therapeutic Targets, 2013, 17, 991-995.	1.5	15
4	Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. Neuron, 2013, 79, 416-438.	3.8	1,401
5	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathologica, 2013, 126, 401-409.	3.9	126
6	Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathologica, 2013, 125, 777-794.	3.9	461
7	FDG PET and the genetics of dementia. Clinical and Translational Imaging, 2013, 1, 235-246.	1.1	2
8	Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic. Cell Reports, 2013, 5, 1178-1186.	2.9	419
9	Frontotemporal lobar degeneration: Diversity of FTLD lesions. Revue Neurologique, 2013, 169, 786-792.	0.6	5
10	Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathologica, 2013, 126, 881-893.	3.9	427
11	Amyotrophic lateral sclerosis: an update on recent genetic insights. Journal of Neurology, 2013, 260, 2917-2927.	1.8	54
12	Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion. Science Translational Medicine, 2013, 5, 208ra149.	5.8	586
13	The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nature Neuroscience, 2013, 16, 1725-1727.	7.1	67
14	Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development (Cambridge), 2013, 140, 4982-4987.	1.2	418
15	Biology and Genetics of Prions Causing Neurodegeneration. Annual Review of Genetics, 2013, 47, 601-623.	3.2	384
16	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurology, The, 2013, 12, 978-988.	4.9	232
17	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathologica Communications, 2013, 1, 68.	2.4	162
18	Genetics of amyotrophic lateral sclerosis: an update. Molecular Neurodegeneration, 2013, 8, 28.	4.4	271

#	Article	IF	Citations
19	C9ORF72 Intermediate Repeat Copies Are a Significant Risk Factor for Parkinson Disease. Annals of Human Genetics, 2013, 77, 351-363.	0.3	69
20	Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: Molecular similarities and differences. Revue Neurologique, 2013, 169, 793-798.	0.6	23
21	Neurodegenerative lesions: Seeding and spreading. Revue Neurologique, 2013, 169, 825-833.	0.6	24
22	Amyotrophic lateral sclerosis: Problems and prospects. Annals of Neurology, 2013, 74, 309-316.	2.8	117
23	The intriguing case of motor neuron disease: ALS and SMA come closer. Biochemical Society Transactions, 2013, 41, 1593-1597.	1.6	29
24	Motoneuronal and muscle-selective removal of ALS-related misfolded proteins. Biochemical Society Transactions, 2013, 41, 1598-1604.	1.6	31
25	RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron, 2013, 80, 415-428.	3.8	785
26	C9orf72-Associated FTD/ALS: When Less Is More. Neuron, 2013, 80, 257-258.	3.8	3
27	The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations. Journal of the Neurological Sciences, 2013, 335, 26-35.	0.3	22
28	Clinical Neurogenetics. Neurologic Clinics, 2013, 31, 929-950.	0.8	35
29	RANTing about C9orf72. Neuron, 2013, 77, 597-598.	3.8	19
30	The changing scene of amyotrophic lateral sclerosis. Nature Reviews Neuroscience, 2013, 14, 248-264.	4.9	860
31	The Unstable Repeatsâ€"Three Evolving Faces of Neurological Disease. Neuron, 2013, 77, 825-843.	3.8	192
32	Researchers identify the protein in c9FTD/ALS inclusions. Nature Reviews Neurology, 2013, 9, 183-183.	4.9	0
33	Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends in Neurosciences, 2013, 36, 450-459.	4.2	151
34	RAN Translation: Fragile X in the Running. Neuron, 2013, 78, 405-408.	3.8	8
35	Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 180-187.	2.8	284
36	Remodeling Neurodegeneration: Somatic Cell Reprogramming-Based Models of Adult Neurological Disorders. Neuron, 2013, 78, 957-969.	3.8	54

#	Article	IF	Citations
37	CGG Repeat-Associated Translation Mediates Neurodegeneration in Fragile X Tremor Ataxia Syndrome. Neuron, 2013, 78, 440-455.	3.8	422
38	Hypermethylation of the CpG Island Near the G4C2 Repeat in ALS with a C9orf72 Expansion. American Journal of Human Genetics, 2013, 92, 981-989.	2.6	241
39	Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathologica, 2013, 126, 859-879.	3.9	298
40	Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathologica, 2013, 126, 829-844.	3.9	506
41	Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathologica, 2013, 126, 895-905.	3.9	263
42	C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathologica, 2013, 126, 845-857.	3.9	289
43	Making sense of the antisense transcripts in C9FTD/ALS. Acta Neuropathologica, 2013, 126, 785-787.	3.9	3
44	Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathologica, 2013, 126, 545-554.	3.9	30
45	RNA That Gets RAN in Neurodegeneration. Science, 2013, 339, 1282-1283.	6.0	9
46	Clinical and Molecular Aspects of Motor Neuron Disease. Colloquium Series on Genomic and Molecular Medicine, 2013, 2, 1-60.	0.2	18
47	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.5	84
48	Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7778-7783.	3.3	306
50	Repeat-associated non-ATG (RAN) translation in neurological disease. Human Molecular Genetics, 2013, 22, R45-R51.	1.4	136
51	Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2013, 26, 466-472.	1.8	22
52	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4530-9.	3.3	508
53	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Human Molecular Genetics, 2013, 22, R77-R87.	1.4	122
54	Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD. Human Molecular Genetics, 2013, 22, 3883-3893.	1.4	72
55	RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4968-77.	3.3	681

#	Article	IF	Citations
56	Genomic editing opens new avenues for zebrafish as a model for neurodegeneration. Journal of Neurochemistry, 2013, 127, 461-470.	2.1	52
57	Stress granules in neurodegeneration â€“ lessons learnt from <scp>TAR DNA</scp> binding protein of 43ÂkDa and fused in sarcoma. FEBS Journal, 2013, 280, 4348-4370.	2.2	151
58	The Disease-associated r(GGGGCC) Repeat from the C9orf72 Gene Forms Tract Length-dependent Uni- and Multimolecular RNA G-quadruplex Structures. Journal of Biological Chemistry, 2013, 288, 9860-9866.	1.6	277
59	Toxic RNA as a driver of disease in a common form of ALS and dementia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7533-7534.	3.3	8
60	Highly Efficient Targeted Mutagenesis in Mice Using TALENs. Genetics, 2013, 195, 703-713.	1.2	62
62	Deletion of C9ORF72 Results in Motor Neuron Degeneration and Stress Sensitivity in C. elegans. PLoS ONE, 2013, 8, e83450.	1.1	158
63	Structural disorder and the loss of RNA homeostasis in aging and neurodegenerative disease. Frontiers in Genetics, 2013, 4, 149.	1.1	6
64	RNA pathogenesis via Toll-like receptor-activated inflammation in expanded repeat neurodegenerative diseases. Frontiers in Molecular Neuroscience, 2013, 6, 25.	1.4	10
65	C9ORF72 Hexanucleotide Repeat Number in Frontotemporal Lobar Degeneration: A Genotype-Phenotype Correlation Study. Journal of Alzheimer's Disease, 2013, 38, 799-808.	1.2	43
66	Oligonucleotide-Based Therapy for FTD/ALS Caused by theC9orf72Repeat Expansion: A Perspective. Journal of Nucleic Acids, 2013, 2013, 1-11.	0.8	8
67	A Case of Logopenic Primary Progressive Aphasia with C9ORF72 Expansion and Cortical Florbetapir Binding. Journal of Alzheimer's Disease, 2014, 42, 413-420.	1.2	14
68	Worming forward: amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in Caenorhabditis elegans. Frontiers in Genetics, 2014, 5, 85.	1.1	50
69	Therapeutic and diagnostic challenges for frontotemporal dementia. Frontiers in Aging Neuroscience, 2014, 6, 204.	1.7	17
70	RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2014, 8, 431.	1.8	25
71	Amyotrophic Lateral Sclerosis - Cell Based Therapy and Novel Therapeutic Development. Experimental Neurobiology, 2014, 23, 207-214.	0.7	20
72	Association of TMEM106B rs1990622 Marker and Frontotemporal Dementia: Evidence for a Recessive Effect and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 43, 325-334.	1.2	9
73	Towards Understanding RNA-Mediated Neurological Disorders. Journal of Genetics and Genomics, 2014, 41, 473-484.	1.7	14
74	Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 829-832.	3.3	296

#	Article	IF	Citations
75	C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathologica, 2014, 128, 485-503.	3.9	300
76	Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLD patients. Human Molecular Genetics, 2014, 23, 5630-5637.	1.4	74
77	Clinicopathologic report of ocular involvement in ALS patients with C9orf72 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 569-580.	1.1	26
78	Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain, 2014, 137, 2040-2051.	3.7	253
79	Antisense Proline-Arginine RAN Dipeptides Linked to C9ORF72-ALS/FTD Form Toxic Nuclear Aggregates that Initiate InÂVitro and InÂVivo Neuronal Death. Neuron, 2014, 84, 1213-1225.	3.8	459
80	Molecular determinants of the axonal mRNA transcriptome. Developmental Neurobiology, 2014, 74, 218-232.	1.5	41
81	RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders. Nucleic Acids Research, 2014, 42, 11849-11864.	6.5	36
82	C9orf72 hexanucleotide repeat expansion analysis in Chinese spastic paraplegia patients. Journal of the Neurological Sciences, 2014, 347, 104-106.	0.3	4
83	C9ORF72â€ALS: P62â€•and ubiquitinâ€aggregation pathology in skeletal muscle. Muscle and Nerve, 2014, 50, 454-455.	1.0	13
84	Relapsingâ€“remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis. Muscle and Nerve, 2014, 50, 456-457.	1.0	6
85	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathologica, 2014, 128, 505-524.	3.9	284
86	Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathologica Communications, 2014, 2, 70.	2.4	103
88	C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. Current Opinion in Neurology, 2014, 27, 515-523.	1.8	67
89	Frontotemporal lobar degeneration: current perspectives. Neuropsychiatric Disease and Treatment, 2014, 10, 297.	1.0	95
90	Multiple System Atrophy and Amyotrophic Lateral Sclerosis in a Family With Hexanucleotide Repeat Expansions inC9orf72. JAMA Neurology, 2014, 71, 771.	4.5	66
91	ExpandedC9ORF72Hexanucleotide Repeat in Depressive Pseudodementia. JAMA Neurology, 2014, 71, 775.	4.5	28
92	Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?. Neurodegenerative Disease Management, 2014, 4, 417-437.	1.2	13
93	Diagnosis and Management of Behavioral Variant Frontotemporal Dementia. Biological Psychiatry, 2014, 75, 574-581.	0.7	84

#	Article	IF	Citations
94	Advances in Cellular Models to Explore the Pathophysiology of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 966-983.	1.9	19
95	C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature, 2014, 507, 195-200.	13.7	779
96	The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathologica, 2014, 127, 347-357.	3.9	164
97	The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathologica, 2014, 127, 333-345.	3.9	150
98	C9ORF72: grabbing a tiger by the tail. Acta Neuropathologica, 2014, 127, 311-318.	3.9	1
99	Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathologica, 2014, 127, 451-458.	3.9	67
100	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	3.9	123
101	Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathologica, 2014, 127, 359-376.	3.9	134
102	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	3.9	133
103	Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia. Acta Neuropathologica, 2014, 127, 377-389.	3.9	43
104	Motoneuron Disease. Handbook of Experimental Pharmacology, 2014, 220, 411-441.	0.9	9
105	Pathways Disrupted in Human ALS Motor Neurons Identified through Genetic Correction of Mutant SOD1. Cell Stem Cell, 2014, 14, 781-795.	5.2	392
106	Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis. Biochemical Pharmacology, 2014, 88, 486-494.	2.0	55
107	Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research. Muscle and Nerve, 2014, 49, 786-803.	1.0	76
108	Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Research, 2014, 1584, 15-21.	1.1	70
109	Advances in motor neurone disease. Journal of the Royal Society of Medicine, 2014, 107, 14-21.	1.1	93
111	Neurodegenerative Diseases. , 2014, , .		3
112	Recent progress in the genetics of motor neuron disease. European Journal of Medical Genetics, 2014, 57, 103-112.	0.7	169

#	Article	IF	Citations
113	Dissection of genetic factors associated with amyotrophic lateral sclerosis. Experimental Neurology, 2014, 262, 91-101.	2.0	145
114	Repeat expansion in C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. Neurobiology of Aging, 2014, 35, 267.e1-267.e7.	1.5	32
115	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathologica, 2014, 128, 525-541.	3.9	154
116	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Human Molecular Genetics, 2014, 23, 749-754.	1.4	98
117	Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases. Molecular Neurobiology, 2014, 50, 721-732.	1.9	48
118	A familial frontotemporal dementia associated with C9orf72 repeat expansion and dysplastic gangliocytoma. Neurobiology of Aging, 2014, 35, 444.e11-444.e14.	1.5	1
119	Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. Acta Neuropathologica, 2014, 127, 151-173.	3.9	44
120	Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Experimental Neurology, 2014, 262, 75-83.	2.0	72
121	Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?. Trends in Molecular Medicine, 2014, 20, 25-35.	3.5	33
122	â€œStructural characterization of the minimal segment of TDP-43 competent for aggregationâ€• Archives of Biochemistry and Biophysics, 2014, 545, 53-62.	1.4	67
123	Frontotemporal lobar degenerationâ€”building on breakthroughs. Nature Reviews Neurology, 2014, 10, 70-72.	4.9	25
124	State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 2014, 17, 17-23.	7.1	1,300
125	C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Human Molecular Genetics, 2014, 23, 3579-3595.	1.4	410
126	G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18201-18206.	3.3	264
127	<scp>C9ORF72</scp> repeatâ€associated nonâ€<scp>ATG</scp>â€translated polypeptides are distributed independently of <scp>TDP</scp>â€43 in a <scp>J</scp>apanese patient with c9<scp>ALS</scp>. Neuropathology and Applied Neurobiology, 2014, 40, 783-788.	1.8	4
128	Repeat-Associated Non-AUG Translation and Its Impact in Neurodegenerative Disease. Neurotherapeutics, 2014, 11, 721-731.	2.1	42
129	The Emerging Roles of MicroRNAs in the Pathogenesis of Frontotemporal Dementiaâ€“Amyotrophic Lateral Sclerosis (FTD-ALS) Spectrum Disorders. Journal of Neurogenetics, 2014, 28, 30-40.	0.6	46
130	ALS-related misfolded protein management in motor neurons and muscle cells. Neurochemistry International, 2014, 79, 70-78.	1.9	27

#	Article	IF	Citations
132	C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science, 2014, 345, 1192-1194.	6.0	632
133	Clogging information flow in ALS. Science, 2014, 345, 1118-1119.	6.0	12
134	Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). Experimental Neurology, 2014, 262, 138-151.	2.0	48
135	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050.	3.8	289
136	Characteristic <scp>RNA</scp> foci of the abnormal hexanucleotide <scp>GGCCUG</scp> repeat expansion in spinocerebellar ataxia type 36 (<scp>A</scp>sidan). European Journal of Neurology, 2014, 21, 1377-1386.	1.7	29
137	Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathologica, 2014, 127, 845-60.	3.9	156
138	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
139	C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology, 2014, 82, 292-299.	1.5	252
140	Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science, 2014, 345, 1139-1145.	6.0	551
141	RNAâ€“protein interactions in unstable microsatellite diseases. Brain Research, 2014, 1584, 3-14.	1.1	51
142	Identification of C9orf72 repeat expansions in patients with amyotrophic lateral sclerosis and frontotemporal dementia in mainland China. Neurobiology of Aging, 2014, 35, 936.e19-936.e22.	1.5	53
143	Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neurobiology of Aging, 2014, 35, 2421.e1-2421.e12.	1.5	40
144	Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging, 2014, 35, 2419.e17-2419.e21.	1.5	21
145	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiology of Aging, 2014, 35, 408-417.	1.5	36
146	Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiology of Aging, 2014, 35, 1214.e1-1214.e6.	1.5	55
147	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging, 2014, 35, 1779.e5-1779.e13.	1.5	234
148	Isoforms of wild type proteins often appear as low molecular weight bands on SDSâ€PAGE. Biotechnology Journal, 2014, 9, 1044-1054.	1.8	20
149	C9ORF72in Dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1435-1436.	0.9	11

#	Article	IF	Citations
150	Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Current Opinion in Genetics and Development, 2014, 26, 6-15.	1.5	104
151	Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Experimental Neurology, 2014, 262, 84-90.	2.0	78
152	C9orf72; abnormal RNA expression is the key. Experimental Neurology, 2014, 262, 102-110.	2.0	15
153	The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2014, 8, 147.	1.8	98
154	Epigenetic modifications of theC9ORF72gene: a potential biomarker of disease?. Future Neurology, 2014, 9, 123-126.	0.9	0
155	Molecular Network Analysis Suggests a Logical Hypothesis for the Pathological Role of C9orf72 in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Journal of Central Nervous System Disease, 2014, 6, JCNSD.S18103.	0.7	27
156	Development of LNA gapmer oligonucleotide based therapy for FTD/ALS caused by the C9orf72 repeat expansion. Neuromuscular Disorders, 2015, 25, S315-S316.	0.3	0
158	Isoformâ€specific antibodies reveal distinct subcellular localizations of <scp>C</scp>9orf72 in amyotrophic lateral sclerosis. Annals of Neurology, 2015, 78, 568-583.	2.8	123
159	Accumulation of dipeptide repeat proteins predates that of <scp>TDP</scp>â€43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in <scp>C9ORF72</scp> gene. Neuropathology and Applied Neurobiology, 2015, 41, 601-612.	1.8	62
160	<scp>C</scp>9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Annals of Neurology, 2015, 78, 426-438.	2.8	225
161	Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathology and Applied Neurobiology, 2015, 41, 858-881.	1.8	168
163	Topology of a G-quadruplex DNA formed by C9orf72 hexanucleotide repeats associated with ALS and FTD. Scientific Reports, 2015, 5, 16673.	1.6	59
164	Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. Npj Aging and Mechanisms of Disease, 2015, 1, .	4.5	24
165	C9ORF72 expression and cellular localization over mouse development. Acta Neuropathologica Communications, 2015, 3, 59.	2.4	27
166	Bioinformatics Data Mining Approach Suggests Coexpression of AGTPBP1 with an ALS-linked Gene C9orf72. Journal of Central Nervous System Disease, 2015, 7, JCNSD.S24317.	0.7	7
167	Promising Targets for the Treatment of Neurodegenerative Diseases. Clinical Pharmacology and Therapeutics, 2015, 98, 492-501.	2.3	22
168	To Know How a Gene Works, We Need to Redefine It First but then, More Importantly, to Let the Cell Itself Decide How to Transcribe and Process Its RNAs. International Journal of Biological Sciences, 2015, 11, 1413-1423.	2.6	20
169	The genetic basis of amyotrophic lateral sclerosis: recent breakthroughs. Advances in Genomics and Genetics, 0, , 327.	0.8	11

#	Article	IF	Citations
170	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2015, 7, 171.	1.7	90
171	Frontotemporal lobar degeneration: old knowledge and new insight into the pathogenetic mechanisms of tau mutations. Frontiers in Aging Neuroscience, 2015, 7, 192.	1.7	39
172	Golgi Fragmentation in ALS Motor Neurons. New Mechanisms Targeting Microtubules, Tethers, and Transport Vesicles. Frontiers in Neuroscience, 2015, 9, 448.	1.4	60
173	Analysis of the GGGGCC Repeat Expansions of the C9orf72 Gene in SCA3/MJD Patients from China. PLoS ONE, 2015, 10, e0130336.	1.1	11
174	Frontotemporal Lobar Degeneration. , 2015, , 57-66.		2
175	Genetics of ALS. , 2015, , 385-409.		0
176	Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2015, 12, 340-351.	2.1	33
177	C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0127376.	1.1	83
178	Gammaâ€synuclein pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 29-37.	1.7	21
179	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathologica, 2015, 129, 469-491.	3.9	218
180	A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders. Journal of Pharmaceutical Sciences, 2015, 104, 1213-1229.	1.6	28
181	Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72â€"a cautionary note. Neurobiology of Aging, 2015, 36, 1224-1226.	1.5	10
182	TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics, 2015, 12, 352-363.	2.1	246
183	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 291-301.	4.9	270
184	A small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. Neurobiology of Aging, 2015, 36, 1601.e1-1601.e5.	1.5	19
185	Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Human Molecular Genetics, 2015, 24, 2426-2441.	1.4	205
186	Emerging role of RNAâ€¢DNA hybrids in C9orf72-linked neurodegeneration. Cell Cycle, 2015, 14, 526-532.	1.3	26
187	From nucleation to widespread propagation: A prion-like concept for ALS. Virus Research, 2015, 207, 94-105.	1.1	53

#	Article	IF	Citations
188	A fruitful endeavor: Modeling ALS in the fruit fly. Brain Research, 2015, 1607, 47-74.	1.1	89
189	Genetic and Molecular Aspects of Frontotemporal Lobar Degeneration. Current Genetic Medicine Reports, 2015, 3, 8-18.	1.9	6
190	The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathologica, 2015, 129, 715-727.	3.9	114
191	The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2015, 12, 326-339.	2.1	46
192	FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathologica, 2015, 130, 525-535.	3.9	126
193	Genotypeâ€“Phenotype Correlations. , 2015, , 29-38.		0
194	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathologica, 2015, 130, 537-555.	3.9	157
195	Single-molecule PCR analysis of an unstable microsatellite for detecting mutations in sperm of mice exposed to chemical mutagens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 775, 26-32.	0.4	13
196	Frontotemporal lobar dementia and amyotrophic lateral sclerosis associated with c9orf72 expansion. Revue Neurologique, 2015, 171, 475-481.	0.6	8
197	Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?. Neurodegenerative Disease Management, 2015, 5, 93-95.	1.2	2
198	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology, 2015, 271, 241-250.	2.0	25
199	The Folding process of Human Profilin-1, a novel protein associated with familial amyotrophic lateral sclerosis. Scientific Reports, 2015, 5, 12332.	1.6	14
200	Mutations of Profilin-1 Associated with Amyotrophic Lateral Sclerosis Promote Aggregation Due to Structural Changes of Its Native State. ACS Chemical Biology, 2015, 10, 2553-2563.	1.6	23
201	Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Progress in Neurobiology, 2015, 133, 1-26.	2.8	99
202	Mutation analysis of C9orf72 in patients with corticobasal syndrome. Neurobiology of Aging, 2015, 36, 2905.e1-2905.e5.	1.5	13
203	Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature Neuroscience, 2015, 18, 1175-1182.	7.1	330
204	Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?. Neurotherapeutics, 2015, 12, 376-383.	2.1	37
205	Gâ€quadruplexes: Emerging roles in neurodegenerative diseases and the nonâ€coding transcriptome. FEBS Letters, 2015, 589, 1653-1668.	1.3	185

#	Article	IF	Citations
206	Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathologica, 2015, 130, 63-75.	3.9	149
208	Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opinion on Biological Therapy, 2015, 15, 935-947.	1.4	30
209	C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science, 2015, 348, 1151-1154.	6.0	332
210	FTD and ALSâ€"translating mouse studies into clinical trials. Nature Reviews Neurology, 2015, 11, 360-366.	4.9	64
211	A network of RNA and protein interactions in Fronto Temporal Dementia. Frontiers in Molecular Neuroscience, 2015, 8, 9.	1.4	22
212	Emerging mechanisms of molecular pathology in ALS. Journal of Clinical Investigation, 2015, 125, 1767-1779.	3.9	244
213	Psychiatric Symptoms in Frontotemporal Dementia: Epidemiology, Phenotypes, and Differential Diagnosis. Biological Psychiatry, 2015, 78, 684-692.	0.7	73
214	Editorial. Journal of Neural Transmission, 2015, 122, 933-936.	1.4	0
215	Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. Neuron, 2015, 87, 1207-1214.	3.8	176
216	Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurologic Clinics, 2015, 33, 855-876.	0.8	199
217	MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain. Cell Reports, 2015, 12, 1159-1168.	2.9	120
218	Frontotemporal dementia. Lancet, The, 2015, 386, 1672-1682.	6.3	690
219	Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathologica Communications, 2015, 3, 47.	2.4	69
220	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiology of Disease, 2015, 82, 445-454.	2.1	33
221	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
222	Drosophila as an In Vivo Model for Human Neurodegenerative Disease. Genetics, 2015, 201, 377-402.	1.2	266
223	Genetics of Frontotemporal Dementia. , 2015, , 75-105.		0
224	C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e1-2660.e8.	1.5	50

#	Article	IF	Citations
225	RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome. Human Molecular Genetics, 2015, 24, 4317-4326.	1.4	91
226	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature, 2015, 525, 56-61.	13.7	835
227	Problems at the nuclear pore. Nature, 2015, 525, 36-37.	13.7	13
228	Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nature Neuroscience, 2015, 18, 1226-1229.	7.1	528
229	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
230	Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathologica, 2015, 130, 845-861.	3.9	204
231	A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opinion on Drug Discovery, 2015, 10, 1099-1118.	2.5	26
232	Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathologica Communications, 2015, 3, 38.	2.4	80
233	Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology, 2015, 85, 2116-2125.	1.5	151
234	C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron, 2015, 88, 892-901.	3.8	249
235	Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron, 2015, 88, 902-909.	3.8	219
236	Epidemiology and molecular mechanism of frontotemporal lobar degeneration/amyotrophic lateral sclerosis with repeat expansion mutation inC9orf72. Journal of Neurogenetics, 2015, 29, 85-94.	0.6	17
237	RAN Translation in Huntington Disease. Neuron, 2015, 88, 667-677.	3.8	275
238	Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Human Molecular Genetics, 2015, 24, 3133-3142.	1.4	91
240	Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 986-995.	0.9	49
242	Invited Review: Decoding the pathophysiological mechanisms that underlie <scp>RNA</scp> dysregulation in neurodegenerative disorders: a review of the current state of the art. Neuropathology and Applied Neurobiology, 2015, 41, 109-134.	1.8	47
243	Biomarker development for C9orf72 repeat expansion in ALS. Brain Research, 2015, 1607, 26-35.	1.1	25
244	Opposing roles of p38 and JNK in a Drosophila model of TDP-43 proteinopathy reveal oxidative stress and innate immunity as pathogenic components of neurodegeneration. Human Molecular Genetics, 2015, 24, 757-772.	1.4	55

#	Article	IF	Citations
245	Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Human Molecular Genetics, 2015, 24, 1630-1645.	1.4	136
246	Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathologica, 2015, 129, 39-52.	3.9	111
247	Characterization of DNA G-quadruplex species forming from C9ORF72 G4C2-expanded repeats associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neurobiology of Aging, 2015, 36, 1091-1096.	1.5	62
248	Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins. Human Molecular Genetics, 2015, 24, 740-756.	1.4	54
250	Heterogeneity of Parkinsonism in Familial Frontotemporal Dementia: Insights from Genetic Clues on the Pathogenesis. , 2016, 6, .		0
252	Genetics of frontotemporal dementia and related disorders. , 0, , 185-196.		1
253	A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease. Frontiers in Cellular Neuroscience, 2016, 10, 204.	1.8	50
254	C9orf72â€™s Interaction with Rab GTPasesâ€"Modulation of Membrane Traffic and Autophagy. Frontiers in Cellular Neuroscience, 2016, 10, 228.	1.8	27
255	Forward Genetic Screen in Caenorhabditis elegans Suggests F57A10.2 and acp-4 As Suppressors of C9ORF72 Related Phenotypes. Frontiers in Molecular Neuroscience, 2016, 9, 113.	1.4	16
256	Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. PLoS Genetics, 2016, 12, e1006443.	1.5	154
257	The genetics of amyotrophic lateral sclerosis: current insights. Degenerative Neurological and Neuromuscular Disease, 2016, 6, 49.	0.7	65
258	Review: Induced pluripotent stem cell models of frontotemporal dementia. Neuropathology and Applied Neurobiology, 2016, 42, 497-520.	1.8	8
259	Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. Journal of Neurochemistry, 2016, 138, 54-70.	2.1	252
260	Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the <scp>C</scp>9<scp>ORF</scp>72 hexanucleotide repeat expansion: a systematic neuropathological review. Neuropathology and Applied Neurobiology, 2016, 42, 547-560.	1.8	34
261	<scp>TDP</scp>â€43 binds and transports <scp>G</scp>â€quadruplexâ€containing m<scp>RNA</scp>s into neurites for local translation. Genes To Cells, 2016, 21, 466-481.	0.5	91
262	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. Annals of Neurology, 2016, 79, 295-305.	2.8	29
263	Old versus New Mechanisms in the Pathogenesis of ALS. Brain Pathology, 2016, 26, 276-286.	2.1	45
264	A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Science Advances, 2016, 2, e1601167.	4.7	210

#	Article	IF	Citations
265	The C9orf72 protein interacts with Rab1a and the <scp>ULK</scp>1 complex to regulate initiation of autophagy. EMBO Journal, 2016, 35, 1656-1676.	3.5	327
266	The FTD-ALS spectrum. , 0, , 68-81.		1
268	Anti-sense DNA d(GGCCCC)n expansions in C9ORF72 form i-motifs and protonated hairpins. Scientific Reports, 2016, 5, 17944.	1.6	73
269	Reduced hn <scp>RNPA</scp> 3 increases C9orf72 repeat <scp>RNA</scp> levels and dipeptideâ€repeat protein deposition. EMBO Reports, 2016, 17, 1314-1325.	2.0	39
270	Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. Human Molecular Genetics, 2017, 26, ddw432.	1.4	82
271	C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production and glomerulonephropathy in mice. Scientific Reports, 2016, 6, 23204.	1.6	213
272	CGG Repeat-Associated Non-AUG Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxic Proteins. Molecular Cell, 2016, 62, 314-322.	4.5	152
273	Recent advances in amyotrophic lateral sclerosis. Journal of Neurology, 2016, 263, 1241-1254.	1.8	67
274	Stress granules at the intersection of autophagy and ALS. Brain Research, 2016, 1649, 189-200.	1.1	93
275	RAN translationâ€"What makes it run?. Brain Research, 2016, 1647, 30-42.	1.1	89
276	Proteostasis impairment in ALS. Brain Research, 2016, 1648, 571-579.	1.1	73
277	There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Research, 2016, 1647, 19-29.	1.1	133
278	The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nature Reviews Neuroscience, 2016, 17, 383-395.	4.9	173
279	C9orf72 isoforms in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. Brain Research, 2016, 1647, 43-49.	1.1	45
280	Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy. Neuroscience and Biobehavioral Reviews, 2016, 66, 127-142.	2.9	11
281	Axonal transport defects are a common phenotype inDrosophilamodels of ALS. Human Molecular Genetics, 2016, 25, ddw105.	1.4	88
282	C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron, 2016, 90, 521-534.	3.8	294
283	Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron, 2016, 90, 535-550.	3.8	437

#	Article	IF	Citations
284	Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs. ACS Chemical Biology, 2016, 11, 1720-1728.	1.6	175
285	Nucleocytoplasmic transport inC9orf72-mediated ALS/FTD. Nucleus, 2016, 7, 132-137.	0.6	27
286	Impaired protein degradation in FTLD and related disorders. Ageing Research Reviews, 2016, 32, 122-139.	5.0	58
287	Identification of a novel loss-of-function C9orf72 splice site mutation in a patient with amyotrophic lateral sclerosis. Neurobiology of Aging, 2016, 47, 219.e1-219.e5.	1.5	17
288	Mechanisms of Dendrite Degeneration in Amyotrophic Lateral Sclerosis. , 2016, , 545-579.		0
289	Cell-to-Cell Transmission of Dipeptide Repeat Proteins Linked to C9orf72 -ALS/FTD. Cell Reports, 2016, 17, 645-652.	2.9	163
291	Poly(GR) in C9ORF72 -Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron, 2016, 92, 383-391.	3.8	323
292	C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Nature Neuroscience, 2016, 19, 1610-1618.	7.1	131
293	Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends in Molecular Medicine, 2016, 22, 769-783.	3.5	103
294	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
295	C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Stem Cells, 2016, 34, 2063-2078.	1.4	195
296	Genetics of <scp>FTLD</scp>: overview and what else we can expect from genetic studies. Journal of Neurochemistry, 2016, 138, 32-53.	2.1	118
297	Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions. Journal of Neurochemistry, 2016, 138, 145-162.	2.1	59
298	The role of dipeptideâ€repeat protein pathology in C9orf72 mutation cases. Neuropathology and Applied Neurobiology, 2016, 42, 217-219.	1.8	3
299	Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. Neuropathology, 2016, 36, 27-38.	0.7	26
300	Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Science Translational Medicine, 2016, 8, 347ra93.	5.8	217
301	FXTAS, FXPOI, and Other Premutation Disorders. , 2016, , .		12
302	The Molecular Biology of Premutation Expanded Alleles. , 2016, , 101-127.		0

#	Article	IF	Citations
303	Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. Journal of Biological Chemistry, 2016, 291, 19437-19448.	1.6	75
304	Catastrophic cliffs: a partial suggestion for selective vulnerability in neurodegenerative diseases. Biochemical Society Transactions, 2016, 44, 659-661.	1.6	12
305	Molecular Pathways Leading toÂtheÂClinical Phenomenology ofÂFrontotemporal Dementia. , 2016, , 533-546.		1
306	Amyotrophic Lateral Sclerosis 1 andÂMany Diseases. , 2016, , 685-712.		3
307	Decoding ALS: from genes to mechanism. Nature, 2016, 539, 197-206.	13.7	1,533
308	Repeatâ€associated nonâ€<scp>AUG</scp> translation from antisense <scp>CCG</scp> repeats in fragile <scp>X</scp> tremor/ataxia syndrome. Annals of Neurology, 2016, 80, 871-881.	2.8	64
309	Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Scientific Reports, 2016, 6, 20877.	1.6	239
310	A Clinical Guide to Frontotemporal Dementias. Focus (American Psychiatric Publishing), 2016, 14, 448-464.	0.4	14
311	Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell, 2016, 167, 789-802.e12.	13.5	363
312	Timing and significance of pathological features inC9orf72expansion-associated frontotemporal dementia. Brain, 2016, 139, 3202-3216.	3.7	136
313	Modelling C9orf72 dipeptide repeat proteins of a physiologically relevant size. Human Molecular Genetics, 2016, 25, ddw327.	1.4	25
315	Pathophysiology and animal models of frontotemporal dementia. , 0, , 197-210.		0
316	ALS and FTD: an epigenetic perspective. Acta Neuropathologica, 2016, 132, 487-502.	3.9	60
317	Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development. Cerebellum, 2016, 15, 599-610.	1.4	15
318	Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathologica, 2016, 132, 159-173.	3.9	109
319	Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron, 2016, 91, 41-55.	3.8	75
320	C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathologica Communications, 2016, 4, 37.	2.4	58
321	Loss of C9 <scp>ORF</scp> 72 impairs autophagy and synergizes with polyQ Ataxinâ€2 to induce motor neuron dysfunction and cell death. EMBO Journal, 2016, 35, 1276-1297.	3.5	343

#	Article	IF	Citations
322	Vulnerability of microRNA biogenesis in FTDâ€“ALS. Brain Research, 2016, 1647, 105-111.	1.1	32
323	Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiology of Aging, 2016, 38, 215.e1-215.e12.	1.5	16
324	Unstable repeat expansions in neurodegenerative diseases: nucleocytoplasmic transport emerges on the scene. Neurobiology of Aging, 2016, 39, 174-183.	1.5	32
325	The â€˜Omicsâ€™ of Amyotrophic Lateral Sclerosis. Trends in Molecular Medicine, 2016, 22, 53-67.	3.5	33
326	C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nature Neuroscience, 2016, 19, 668-677.	7.1	268
327	The Glycine-Alanine Dipeptide Repeat from C9orf72 Hexanucleotide Expansions Forms Toxic Amyloids Possessing Cell-to-Cell Transmission Properties. Journal of Biological Chemistry, 2016, 291, 4903-4911.	1.6	73
328	ALS biomarkers for therapy development: State of the field and future directions. Muscle and Nerve, 2016, 53, 169-182.	1.0	85
329	Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDPâ€43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathology and Applied Neurobiology, 2016, 42, 242-254.	1.8	61
330	Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. CNS Drugs, 2016, 30, 227-243.	2.7	36
331	Pathogenic C9ORF72 Antisense Repeat RNA Forms a Double Helix with Tandem C:C Mismatches. Biochemistry, 2016, 55, 1283-1286.	1.2	31
332	G-quadruplex formation of oligonucleotides containing ALS and FTD related GGGGCC repeat. Frontiers of Chemical Science and Engineering, 2016, 10, 222-237.	2.3	7
333	Dendritic Spine Pathology in Neurodegenerative Diseases. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 221-250.	9.6	161
334	Failure of RQC machinery causes protein aggregation and proteotoxic stress. Nature, 2016, 531, 191-195.	13.7	185
335	Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathologica Communications, 2016, 4, 18.	2.4	46
336	Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Human Molecular Genetics, 2016, 25, 1803-1813.	1.4	146
337	Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis. Science Signaling, 2016, 9, ra2.	1.6	83
338	An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Current Opinion in Neurobiology, 2016, 36, 99-106.	2.0	59
339	Presence of inclusions positive for polyglycine containing protein, FMRpolyG, indicates that repeat-associated non-AUG translation plays a role in fragile X-associated primary ovarian insufficiency. Human Reproduction, 2016, 31, 158-168.	0.4	87

#	Article	IF	Citations
340	Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells. Annual Review of Pharmacology and Toxicology, 2016, 56, 123-140.	4.2	58
341	The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Molecular Psychiatry, 2016, 21, 1112-1124.	4.1	201
342	Association of the functional SNP rs2275294 in ZNF512B with risk of amyotrophic lateral sclerosis and Parkinson's disease in Han Chinese. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 142-147.	1.1	12
343	Modeling ALS and FTD with iPSC-derived neurons. Brain Research, 2017, 1656, 88-97.	1.1	56
344	Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDPâ€43 subcellular distribution. Neuropathology and Applied Neurobiology, 2017, 43, 133-153.	1.8	23
345	C9ORF72 Regulates Stress Granule Formation and Its Deficiency Impairs Stress Granule Assembly, Hypersensitizing Cells to Stress. Molecular Neurobiology, 2017, 54, 3062-3077.	1.9	76
346	Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathology, 2017, 27, 723-736.	2.1	112
347	Biological Spectrum of Amyotrophic Lateral Sclerosis Prions. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024133.	2.9	24
348	Toxic PR _n poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1111-E1117.	3.3	202
349	Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. Molecular Neurodegeneration, 2017, 12, 6.	4.4	57
350	c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA. Cell Chemical Biology, 2017, 24, 141-148.	2.5	29
351	Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome. Neuron, 2017, 93, 331-347.	3.8	194
352	Psychiatric Presentations of C9orf72 Mutation: What Are the Diagnostic Implications for Clinicians?. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 195-205.	0.9	58
353	Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function. Journal of Biological Chemistry, 2017, 292, 5089-5100.	1.6	42
354	C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease. Traffic, 2017, 18, 267-276.	1.3	54
355	Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathologica, 2017, 134, 187-205.	3.9	288
356	Frontotemporal dementia. , 2017, , 199-249.		1
357	Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathologica, 2017, 134, 241-254.	3.9	99

#	Article	IF	Citations
358	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
359	Modelling amyotrophic lateral sclerosis: progress and possibilities. DMM Disease Models and Mechanisms, 2017, 10, 537-549.	1.2	156
360	Bidirectional nucleolar dysfunction in C9orf72 frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2017, 5, 29.	2.4	43
361	Protein sequestration as a normal function of long noncoding RNAs and a pathogenic mechanism of RNAs containing nucleotide repeat expansions. Human Genetics, 2017, 136, 1247-1263.	1.8	26
362	Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathologica, 2017, 134, 79-96.	3.9	83
363	Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders. Human Genetics, 2017, 136, 1215-1235.	1.8	15
364	Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients. Cell Reports, 2017, 19, 2244-2256.	2.9	82
365	The UPR ER : Sensor and Coordinator of Organismal Homeostasis. Molecular Cell, 2017, 66, 761-771.	4.5	227
366	Imaging and fluid biomarkers in frontotemporal dementia. Nature Reviews Neurology, 2017, 13, 406-419.	4.9	163
367	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
368	From sperm to offspring: Assessing the heritable genetic consequences of paternal smoking and potential public health impacts. Mutation Research - Reviews in Mutation Research, 2017, 773, 26-50.	2.4	92
369	Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy. Journal of Molecular Medicine, 2017, 95, 705-718.	1.7	18
370	New routes in frontotemporal dementia drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 659-671.	2.5	8
371	Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells. Brain Pathology, 2017, 27, 518-524.	2.1	9
372	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2017, 140, 887-897.	3.7	126
373	Viral delivery of C9ORF72 hexanucleotide repeat expansions in mice lead to repeat length dependent neuropathology and behavioral deficits.. DMM Disease Models and Mechanisms, 2017, 10, 859-868.	1.2	25
374	RNA G-Quadruplexes in Biology: Principles and Molecular Mechanisms. Journal of Molecular Biology, 2017, 429, 2127-2147.	2.0	324
375	C9orf72 mutations do not influence the tau signature of amyotrophic lateral sclerosis with cognitive impairment (ALSci). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 549-554.	1.1	2

#	Article	IF	Citations
376	Genetics of Amyotrophic Lateral Sclerosis. , 2017, , 43-59.		2
377	Doseâ€“response mutation and spectrum analyses reveal similar responses at two microsatellite loci in benzo(a)pyrene-exposed mouse spermatogonia. Mutagenesis, 2017, 32, 463-470.	1.0	2
378	Genetic models of C9orf72: what is toxic?. Current Opinion in Genetics and Development, 2017, 44, 92-101.	1.5	50
379	New developments in RAN translation: insights from multiple diseases. Current Opinion in Genetics and Development, 2017, 44, 125-134.	1.5	81
380	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Human Molecular Genetics, 2017, 26, 1732-1746.	1.4	62
381	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	179
382	Antibodies inhibit transmission and aggregation of C9orf72 polyâ€•<scp>GA</scp> dipeptide repeat proteins. EMBO Molecular Medicine, 2017, 9, 687-702.	3.3	70
383	Sigma Receptors: Their Role in Disease and as Therapeutic Targets. Advances in Experimental Medicine and Biology, 2017, , .	0.8	16
384	Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Molecular Cell, 2017, 65, 1044-1055.e5.	4.5	437
385	Sigma-1 Receptor in Motoneuron Disease. Advances in Experimental Medicine and Biology, 2017, 964, 235-254.	0.8	11
386	Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024554.	2.9	56
387	Molecular Genetics of Neurodegenerative Dementias. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023705.	2.3	51
388	Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 119-134.	2.1	74
389	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.1	17
390	Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024117.	2.9	149
391	Structure and Dynamics of DNA and RNA Double Helices Obtained from the GGGGCC and CCCCGG Hexanucleotide Repeats That Are the Hallmark of C9FTD/ALS Diseases. ACS Chemical Neuroscience, 2017, 8, 578-591.	1.7	31
392	C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. Human Molecular Genetics, 2017, 26, 4765-4777.	1.4	64
393	Regulation of mRNA Translation in Neuronsâ€”A Matter of Life and Death. Neuron, 2017, 96, 616-637.	3.8	188

#	Article	IF	Citations
394	Non-AUG translation: a new start for protein synthesis in eukaryotes. Genes and Development, 2017, 31, 1717-1731.	2.7	322
395	The roles of intrinsic disorder-based liquid-liquid phase transitions in the â€œDr. Jekyllâ€“Mr. Hydeâ€• behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Autophagy, 2017, 13, 2115-2162.	4.3	48
396	Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. Neuron, 2017, 96, 285-297.	3.8	208
397	The hexanucleotide hex. Nature, 2017, 550, S106-S108.	13.7	1
398	Dysregulated molecular pathways in amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum disorder. EMBO Journal, 2017, 36, 2931-2950.	3.5	150
399	RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2. Neuron, 2017, 95, 1292-1305.e5.	3.8	116
400	Cell-type specific differences in promoter activity of the ALS-linked C9orf72 mouse ortholog. Scientific Reports, 2017, 7, 5685.	1.6	9
401	RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nature Communications, 2017, 8, 2005.	5.8	172
402	Rethinking Unconventional Translation in Neurodegeneration. Cell, 2017, 171, 994-1000.	13.5	56
403	RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Science Translational Medicine, 2017, 9, .	5.8	72
404	Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Human Molecular Genetics, 2017, 26, 3421-3431.	1.4	101
405	Motoneuron Disease: Basic Science. Advances in Neurobiology, 2017, 15, 163-190.	1.3	5
406	SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nature Communications, 2017, 8, 16063.	5.8	106
407	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
408	Protein Disulphide Isomerases: emerging roles of PDI and ERp57 in the nervous system and as therapeutic targets for ALS. Expert Opinion on Therapeutic Targets, 2017, 21, 37-49.	1.5	16
409	Cross-Î² Polymerization of Low Complexity Sequence Domains. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023598.	2.3	51
410	Intrinsic disorder in proteins involved in amyotrophic lateral sclerosis. Cellular and Molecular Life Sciences, 2017, 74, 1297-1318.	2.4	42
411	ALS and FTD linked GGGGCC-repeat containing DNA oligonucleotide folds into two distinct G-quadruplexes. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1237-1245.	1.1	24

#	Article	IF	Citations
412	C9ORF72 and UBQLN2 mutations are causes of amyotrophic lateral sclerosis in New Zealand: a genetic and pathologic study using banked human brain tissue. Neurobiology of Aging, 2017, 49, 214.e1-214.e5.	1.5	18
413	C9ORF72 is a GDP/GTP exchange factor for Rab8 and Rab39 and regulates autophagy. Small GTPases, 2017, 8, 181-186.	0.7	69
414	Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Brain, 2017, 140, 13-26.	3.7	53
415	R Loops and Links to Human Disease. Journal of Molecular Biology, 2017, 429, 3168-3180.	2.0	147
416	Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene. Neuroscience Letters, 2017, 636, 16-26.	1.0	36
417	ALS/FTD-Associated C9ORF72 Repeat RNA Promotes Phase Transitions InÂVitro and in Cells. Cell Reports, 2017, 21, 3573-3584.	2.9	161
418	Genetic approaches to neurodegenerative disease. , 0, , 57-76.		0
419	Autophagy-Lysosome Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. , 0, , .		4
420	Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions. Molecules, 2017, 22, 2027.	1.7	49
421	Structural Characteristics of Simple RNA Repeats Associated with Disease and their Deleterious Protein Interactions. Frontiers in Cellular Neuroscience, 2017, 11, 97.	1.8	65
422	Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis. Frontiers in Cellular Neuroscience, 2017, 11, 126.	1.8	11
423	Fragile X-Associated Tremor/Ataxia Syndrome: From Molecular Pathogenesis to Development of Therapeutics. Frontiers in Cellular Neuroscience, 2017, 11, 128.	1.8	49
424	RNA Misprocessing in C9orf72-Linked Neurodegeneration. Frontiers in Cellular Neuroscience, 2017, 11, 195.	1.8	32
425	The Enigmatic Role of C9ORF72 in Autophagy. Frontiers in Neuroscience, 2017, 11, 442.	1.4	49
426	Unraveling the Role of RNA Mediated Toxicity of C9orf72 Repeats in C9-FTD/ALS. Frontiers in Neuroscience, 2017, 11, 711.	1.4	46
427	The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD. Frontiers in Molecular Neuroscience, 2017, 10, 35.	1.4	207
428	Dysregulation of RNA Binding Protein Aggregation in Neurodegenerative Disorders. Frontiers in Molecular Neuroscience, 2017, 10, 89.	1.4	117
429	Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum. Frontiers in Molecular Neuroscience, 2017, 10, 119.	1.4	58

#	Article	IF	Citations
430	The Role of the Heat Shock Protein B8 (HSPB8) in Motoneuron Diseases. Frontiers in Molecular Neuroscience, 2017, 10, 176.	1.4	54
431	Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand. Frontiers in Molecular Neuroscience, 2017, 10, 263.	1.4	123
432	Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload. Current Topics in Developmental Biology, 2017, 121, 111-171.	1.0	26
433	C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. Human Molecular Genetics, 2017, 26, 1133-1145.	1.4	23
434	The essential and downstream common proteins of amyotrophic lateral sclerosis: A protein-protein interaction network analysis. PLoS ONE, 2017, 12, e0172246.	1.1	14
435	RNA biology of disease-associated microsatellite repeat expansions. Acta Neuropathologica Communications, 2017, 5, 63.	2.4	58
436	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2017, 5, 68.	2.4	34
437	Recent advances in the molecular genetics of frontotemporal lobar degeneration. Functional Neurology, 2017, 32, 7.	1.3	29
438	mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain Research, 2018, 1693, 75-91.	1.1	56
439	Disruption of ERâ"mitochondria signalling in fronto-temporal dementia and related amyotrophic lateral sclerosis. Cell Death and Disease, 2018, 9, 327.	2.7	54
440	Pathomechanisms of TDPâ€43 in neurodegeneration. Journal of Neurochemistry, 2018, 146, 7-20.	2.1	157
441	Interrelationship between the Levels of C9orf72 and Amyloid-Î² Protein Precursor and Amyloid-Î² in Human CellsÂand Brain Samples. Journal of Alzheimer's Disease, 2018, 62, 269-278.	1.2	3
442	CRISPRâ€"Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nature Genetics, 2018, 50, 603-612.	9.4	178
443	Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Scientific Reports, 2018, 8, 6030.	1.6	54
444	Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell, 2018, 173, 958-971.e17.	13.5	303
445	C9orf72-associated neurodegeneration in ALS-FTD: breaking new ground in ribosomal RNA and nucleolar dysfunction. Cell and Tissue Research, 2018, 373, 351-360.	1.5	26
446	Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. Brain Research, 2018, 1693, 98-108.	1.1	65
447	Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. Cell Death and Differentiation, 2018, 25, 648-662.	5.0	55

#	Article	IF	Citations
448	In Situ Structure of Neuronal C9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment. Cell, 2018, 172, 696-705.e12.	13.5	311
449	Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nature Medicine, 2018, 24, 313-325.	15.2	445
450	Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. Acta Neuropathologica, 2018, 135, 445-457.	3.9	59
451	Characterizations of distinct parallel and antiparallel G-quadruplexes formed by two-repeat ALS and FTD related GGGGCC sequence. Scientific Reports, 2018, 8, 2366.	1.6	38
452	Structural and Dynamical Characterization of DNA and RNA Quadruplexes Obtained from the GGGGCC and GGGCCT Hexanucleotide Repeats Associated with C9FTD/ALS and SCA36 Diseases. ACS Chemical Neuroscience, 2018, 9, 1104-1117.	1.7	22
453	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
454	CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nature Communications, 2018, 9, 152.	5.8	123
455	Matrin 3 Is a Component of Neuronal Cytoplasmic Inclusions of Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2018, 188, 507-514.	1.9	36
456	C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2Î± phosphorylation. Nature Communications, 2018, 9, 51.	5.8	166
457	A C9orf72 ALS/FTD Ortholog Acts in Endolysosomal Degradation and Lysosomal Homeostasis. Current Biology, 2018, 28, 1522-1535.e5.	1.8	75
458	Insights into C9ORF72-Related ALS/FTD from Drosophila and iPSC Models. Trends in Neurosciences, 2018, 41, 457-469.	4.2	42
459	Autophagy and lysosomal pathways in nervous system disorders. Molecular and Cellular Neurosciences, 2018, 91, 167-208.	1.0	22
460	All in the Family: Repeats and ALS/FTD. Trends in Neurosciences, 2018, 41, 247-250.	4.2	8
461	Protein Phase Separation: A New Phase in Cell Biology. Trends in Cell Biology, 2018, 28, 420-435.	3.6	1,439
462	C9orf72 plays a central role in Rab GTPase-dependent regulation of autophagy. Small GTPases, 2018, 9, 399-408.	0.7	45
463	Disease Mechanisms ofC9ORF72Repeat Expansions. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a024224.	2.9	75
464	The Genetics ofC9orf72Expansions. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a026757.	2.9	19
465	The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases. Cell Stress and Chaperones, 2018, 23, 1-12.	1.2	69

#	Article	IF	Citations
466	Detection of expanded RNA repeats using thermostable group II intron reverse transcriptase. Nucleic Acids Research, 2018, 46, e1-e1.	6.5	14
467	Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. Autophagy, 2018, 14, 534-551.	4.3	66
468	A Solid-State Conceptualization of Information Transfer from Gene to Message to Protein. Annual Review of Biochemistry, 2018, 87, 351-390.	5.0	113
469	Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathologica, 2018, 135, 459-474.	3.9	152
470	Gâ€quadruplexâ€binding small molecules ameliorate C9orf72 <scp>FTD</scp> / <scp>ALS</scp> pathology inÂvitro and inÂvivo. EMBO Molecular Medicine, 2018, 10, 22-31.	3.3	178
471	In vivo genome editing via the HITI method as a tool for gene therapy. Journal of Human Genetics, 2018, 63, 157-164.	1.1	90
472	Immunohistochemical detection of C9orf72 protein in frontotemporal lobar degeneration and motor neurone disease: patterns of immunostaining and an evaluation of commercial antibodies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 102-111.	1.1	10
473	Rab-dependent cellular trafficking and amyotrophic lateral sclerosis. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 623-651.	2.3	12
474	Properties of LINE-1 proteins and repeat element expression in the context of amyotrophic lateral sclerosis. Mobile DNA, 2018, 9, 35.	1.3	37
475	Non-coding RNA in C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia: A perfect storm of dysfunction. Non-coding RNA Research, 2018, 3, 178-187.	2.4	13
476	New Antibody-Free Mass Spectrometry-Based Quantification Reveals That C9ORF72 Long Protein Isoform Is Reduced in the Frontal Cortex of Hexanucleotide-Repeat Expansion Carriers. Frontiers in Neuroscience, 2018, 12, 589.	1.4	23
477	A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-Î± mediates C9orf72-related neurodegeneration. Brain, 2018, 141, 2908-2924.	3.7	75
478	Therapeutic Genome Editing for Myotonic Dystrophy Type 1ÂUsing CRISPR/Cas9. Molecular Therapy, 2018, 26, 2617-2630.	3.7	48
479	The prolineâ€“arginine repeat protein linked to C9-ALS/FTD causes neuronal toxicity by inhibiting the DEAD-box RNA helicase-mediated ribosome biogenesis. Cell Death and Disease, 2018, 9, 975.	2.7	28
480	NMR structure of a G-quadruplex formed by four d(G4C2) repeats: insights into structural polymorphism. Nucleic Acids Research, 2018, 46, 11605-11617.	6.5	34
481	The identity and function of microglia in neurodegeneration. Nature Immunology, 2018, 19, 1048-1058.	7.0	241
482	A C9orf72â€“CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress. Genes and Development, 2018, 32, 1380-1397.	2.7	49
483	Repeat-associated non-ATG (RAN) translation. Journal of Biological Chemistry, 2018, 293, 16127-16141.	1.6	81

#	Article	IF	Citations
484	Characterization of membrane penetration and cytotoxicity of C9orf72-encoding arginine-rich dipeptides. Scientific Reports, 2018, 8, 12740.	1.6	44
485	Encoding activities of non-coding RNAs. Theranostics, 2018, 8, 2496-2507.	4.6	42
486	<scp>SCA</scp> 8 <scp>RAN</scp> polySer protein preferentially accumulates in white matter regions and is regulated by <scp>eIF</scp> 3F. EMBO Journal, 2018, 37, .	3.5	50
487	Biological functions, regulatory mechanisms, and disease relevance of RNA localization pathways. FEBS Letters, 2018, 592, 2948-2972.	1.3	32
489	RNP-Granule Assembly via Ataxin-2 Disordered Domains Is Required for Long-Term Memory and Neurodegeneration. Neuron, 2018, 98, 754-766.e4.	3.8	98
490	Mechanisms of protein toxicity in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2018, 75, 3159-3180.	2.4	103
491	Amyotrophic Lateral Sclerosis Model. Advances in Experimental Medicine and Biology, 2018, 1076, 79-95.	0.8	11
492	The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis. Genes and Development, 2018, 32, 929-943.	2.7	65
493	Amyotrophic lateral sclerosis and non-tau frontotemporal lobar degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 369-381.	1.0	16
494	The Microglial Response to Neurodegenerative Disease. Advances in Immunology, 2018, 139, 1-50.	1.1	22
495	1,3-Di(quinolin-2-yl)guanidine binds to GGCCCC hexanucleotide repeat DNA in C9ORF72. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2364-2368.	1.0	3
496	Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nature Medicine, 2018, 24, 1136-1142.	15.2	241
497	Repeat Expansion Disease Models. Advances in Experimental Medicine and Biology, 2018, 1076, 63-78.	0.8	9
498	Drosophila Models for Human Diseases. Advances in Experimental Medicine and Biology, 2018, , .	0.8	13
499	Drosophila as a Model to Gain Insight into the Role of lncRNAs in Neurological Disorders. Advances in Experimental Medicine and Biology, 2018, 1076, 119-146.	0.8	12
500	Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. Acta Neuropathologica Communications, 2018, 6, 42.	2.4	20
501	Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathologica Communications, 2018, 6, 72.	2.4	87
503	Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis. Cell Transplantation, 2018, 27, 1301-1312.	1.2	14

#	Article	IF	Citations
504	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	1.7	40
505	Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosisâ€"Frontotemporal Spectrum Disorder (ALS-FTSD). A Review. Frontiers in Neuroscience, 2018, 12, 259.	1.4	24
506	Autophagy in Age-Associated Neurodegeneration. Cells, 2018, 7, 37.	1.8	87
507	Patient-Derived iPSCs and iNsâ€"Shedding New Light on the Cellular Etiology of Neurodegenerative Diseases. Cells, 2018, 7, 38.	1.8	5
508	(C2G4)n repeat expansion sequences from the C9orf72 gene form an unusual DNA higher-order structure in the pH range of 5-6. PLoS ONE, 2018, 13, e0198418.	1.1	8
509	Molecular Chaperones Regulating the Dynamics, Composition and Functionality of RNP Granules: Implications for Age-Related Diseases. Heat Shock Proteins, 2018, , 205-222.	0.2	0
510	Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathologica Communications, 2018, 6, 55.	2.4	24
511	Drosophila models of amyotrophic lateral sclerosis with defects in RNA metabolism. Brain Research, 2018, 1693, 109-120.	1.1	14
512	Genotypic and Phenotypic Heterogeneity in Amyotrophic Lateral Sclerosis. , 2018, , 279-295.		3
513	C9ORF72 dipeptide repeat poly-GA inclusions promote intracellular aggregation of phosphorylated TDP-43. Human Molecular Genetics, 2018, 27, 2658-2670.	1.4	39
514	C9orf72-mediated ALS and FTD: multiple pathways to disease. Nature Reviews Neurology, 2018, 14, 544-558.	4.9	478
515	Repeat-Associated Non-ATG (RAN) Translation in Fuchs' Endothelial Corneal Dystrophy. , 2018, 59, 1888.		53
516	Ataxinâ€2: A versatile posttranscriptional regulator and its implication in neural function. Wiley Interdisciplinary Reviews RNA, 2018, 9, e1488.	3.2	22
517	Repeat-Associated Non-ATG Translation in Neurological Diseases. Cold Spring Harbor Perspectives in Biology, 2018, 10, a033019.	2.3	33
518	An Epigenetic Spin to ALS and FTD. Advances in Neurobiology, 2018, 20, 1-29.	1.3	5
519	Lost in Translation: Evidence for Protein Synthesis Deficits in ALS/FTD and Related Neurodegenerative Diseases. Advances in Neurobiology, 2018, 20, 283-301.	1.3	38
520	Stress Granules and ALS: A Case of Causation or Correlation?. Advances in Neurobiology, 2018, 20, 173-212.	1.3	39
521	Deregulation of RNA Metabolism in Microsatellite Expansion Diseases. Advances in Neurobiology, 2018, 20, 213-238.	1.3	5

#	Article	IF	Citations
522	Autophagy and mitophagy in ALS. Neurobiology of Disease, 2019, 122, 35-40.	2.1	125
523	Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs. Neurobiology of Disease, 2019, 132, 104562.	2.1	20
524	RAN translation down. Nature Neuroscience, 2019, 22, 1379-1380.	7.1	6
525	Liquidâ€“Liquid Phase Separation in Disease. Annual Review of Genetics, 2019, 53, 171-194.	3.2	553
526	The nucleolus functions as a phase-separated protein quality control compartment. Science, 2019, 365, 342-347.	6.0	348
527	Extracellular vesicles and their diagnostic potential in amyotrophic lateral sclerosis. Clinica Chimica Acta, 2019, 497, 27-34.	0.5	12
528	Molecular genetics of congenital myotonic dystrophy. Neurobiology of Disease, 2019, 132, 104533.	2.1	42
529	Methods to identify and optimize small molecules interacting with RNA (SMIRNAs). Drug Discovery Today, 2019, 24, 2002-2016.	3.2	22
530	RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats. Nature Neuroscience, 2019, 22, 1383-1388.	7.1	87
531	High-throughput screening yields several small-molecule inhibitors of repeat-associated non-AUG translation. Journal of Biological Chemistry, 2019, 294, 18624-18638.	1.6	32
532	C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain, 2019, 142, 3771-3790.	3.7	59
533	Production of poly(GA) in C9ORF72 patient motor neurons derived from induced pluripotent stem cells. Acta Neuropathologica, 2019, 138, 1099-1101.	3.9	27
534	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
535	CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation. Neuron, 2019, 104, 885-898.e8.	3.8	107
536	C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport. Scientific Reports, 2019, 9, 15728.	1.6	47
537	C9orf72 Proteins Regulate Autophagy and Undergo Autophagosomal or Proteasomal Degradation in a Cell Type-Dependent Manner. Cells, 2019, 8, 1233.	1.8	19
538	Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Neurotherapeutics, 2019, 16, 1115-1132.	2.1	30
539	Alternative role of noncoding RNAs: coding and noncoding properties. Journal of Zhejiang University: Science B, 2019, 20, 920-927.	1.3	1

#	Article	IF	Citations
540	Phosphoproteomics of Acute Cell Stressors Targeting Exercise Signaling Networks Reveal Drug Interactions Regulating Protein Secretion. Cell Reports, 2019, 29, 1524-1538.e6.	2.9	30
541	TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Communications, 2019, 1, fcz014.	1.5	28
542	Synaptic localization of C9orf72 regulates post-synaptic glutamate receptor 1 levels. Acta Neuropathologica Communications, 2019, 7, 161.	2.4	49
543	Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2019, 12, 262.	1.4	101
544	Anthocyanins and Their Metabolites as Therapeutic Agents for Neurodegenerative Disease. Antioxidants, 2019, 8, 333.	2.2	92
545	Neurons Induced From Fibroblasts of c9ALS/FTD Patients Reproduce the Pathology Seen in the Central Nervous System. Frontiers in Neuroscience, 2019, 13, 935.	1.4	2
546	Repeat-associated non-AUG (RAN) translation mechanisms are running into focus for GGGGCC-repeat associated ALS/FTD. Progress in Neurobiology, 2019, 183, 101697.	2.8	10
547	Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology, 2019, 93, e1605-e1617.	1.5	29
548	C9ORF72 protein function and immune dysregulation in amyotrophic lateral sclerosis. Neuroscience Letters, 2019, 713, 134523.	1.0	19
549	Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain, 2019, 142, 586-605.	3.7	84
550	SQSTM1/p62: A Potential Target for Neurodegenerative Disease. ACS Chemical Neuroscience, 2019, 10, 2094-2114.	1.7	107
551	New pathologic mechanisms in nucleotide repeat expansion disorders. Neurobiology of Disease, 2019, 130, 104515.	2.1	60
552	Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathologica, 2019, 138, 783-793.	3.9	19
553	Granulin in Frontotemporal Lobar Degeneration: Molecular Mechanisms of the Disease. Frontiers in Neuroscience, 2019, 13, 395.	1.4	14
554	Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies. Acta Neuropathologica Communications, 2019, 7, 65.	2.4	20
555	L3MBTL1 regulates ALS/FTD-associated proteotoxicity and quality control. Nature Neuroscience, 2019, 22, 875-886.	7.1	10
556	C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nature Neuroscience, 2019, 22, 851-862.	7.1	161
557	Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9ORF72 -ALS/FTD. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9628-9633.	3.3	64

#	Article	IF	Citations
558	Rare variants in MYH15 modify amyotrophic lateral sclerosis risk. Human Molecular Genetics, 2019, 28, 2309-2318.	1.4	4
559	Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions. Neuron, 2019, 102, 294-320.	3.8	176
560	Dissecting Motor Neuron Disease With Drosophila melanogaster. Frontiers in Neuroscience, 2019, 13, 331.	1.4	12
561	eIF4B and eIF4H mediate GR production from expanded G4C2 in a Drosophila model for C9orf72-associated ALS. Acta Neuropathologica Communications, 2019, 7, 62.	2.4	38
562	Molecular dynamics study of structure, folding, and aggregation of poly-glycine-alanine (Poly-GA). Journal of Chemical Physics, 2019, 150, 144307.	1.2	7
563	A Peptidylic Inhibitor for Neutralizing (GGGGCC)-Associated Neurodegeneration in C9ALS-FTD. Molecular Therapy - Nucleic Acids, 2019, 16, 172-185.	2.3	18
564	Bridging biophysics and neurology: aberrant phase transitions in neurodegenerative disease. Nature Reviews Neurology, 2019, 15, 272-286.	4.9	150
565	Genetic Convergence Brings Clarity to the Enigmatic Red Line in ALS. Neuron, 2019, 101, 1057-1069.	3.8	111
566	An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology. Acta Neuropathologica, 2019, 137, 855-858.	3.9	12
567	Repeat-Associated Non-ATG Translation: Molecular Mechanisms and Contribution to Neurological Disease. Annual Review of Neuroscience, 2019, 42, 227-247.	5.0	62
568	HR23B pathology preferentially co-localizes with p62, pTDP-43 and poly-GA in C9ORF72-linked frontotemporal dementia and amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2019, 7, 39.	2.4	9
569	Repeat-associated non-AUG (RAN) translation: insights from pathology. Laboratory Investigation, 2019, 99, 929-942.	1.7	39
570	Spontaneous driving forces give rise to proteinâ˜'RNA condensates with coexisting phases and complex material properties. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7889-7898.	3.3	365
571	ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathologica, 2019, 138, 49-65.	3.9	48
572	Reactivation of nonsense-mediated mRNA decay protects against C9orf72 dipeptide-repeat neurotoxicity. Brain, 2019, 142, 1349-1364.	3.7	45
573	Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathologica, 2019, 137, 859-877.	3.9	123
574	RNA Dysregulation in Amyotrophic Lateral Sclerosis. Frontiers in Genetics, 2018, 9, 712.	1.1	134
575	Translational control in brain pathologies: biological significance and therapeutic opportunities. Acta Neuropathologica, 2019, 137, 535-555.	3.9	23

#	Article	IF	Citations
576	Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Molecular Neurodegeneration, 2019, 14, 9.	4.4	111
577	Nuclear RNA foci from C9ORF72 expansion mutation form paraspeckle-like bodies. Journal of Cell Science, 2019, 132, .	1.2	36
578	Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Journal of Molecular Biology, 2019, 431, 1818-1829.	2.0	49
579	Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science, 2019, 363, .	6.0	181
580	From Neuronal Differentiation of iPSCs to 3D Neural Organoids: Modeling of Neurodegenerative Diseases. , 2019, , .		1
581	<scp>DDX</scp> 3X and specific initiation factors modulate <scp>FMR</scp> 1 repeatâ€associated nonâ€AUGâ€initiated translation. EMBO Reports, 2019, 20, e47498.	2.0	53
582	Transcription elongation factor AFF2/FMR2 regulates expression of expanded GGGGCC repeat-containing C9ORF72 allele in ALS/FTD. Nature Communications, 2019, 10, 5466.	5.8	40
583	Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases. Acta Neuropathologica Communications, 2019, 7, 189.	2.4	22
584	Mechanisms of Immune Activation by c9orf72-Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience, 2019, 13, 1298.	1.4	28
585	Links Between the C9orf72 Repeat Expansion and Psychiatric Symptoms. Current Neurology and Neuroscience Reports, 2019, 19, 93.	2.0	18
586	Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Molecular Brain, 2019, 12, 100.	1.3	122
587	Glycine-alanine dipeptide repeats spread rapidly in a repeat length- and age-dependent manner in the fly brain. Acta Neuropathologica Communications, 2019, 7, 209.	2.4	17
588	Primary Neurons and Differentiated NSC-34 Cells Are More Susceptible to Arginine-Rich ALS Dipeptide Repeat Protein-Associated Toxicity than Non-Differentiated NSC-34 and CHO Cells. International Journal of Molecular Sciences, 2019, 20, 6238.	1.8	13
589	Peptides encoded by noncoding genes: challenges and perspectives. Signal Transduction and Targeted Therapy, 2019, 4, 57.	7.1	22
590	The Biology of mRNA: Structure and Function. Advances in Experimental Medicine and Biology, 2019, , .	0.8	3
591	Review: Molecular pathology of frontotemporal lobar degenerations. Neuropathology and Applied Neurobiology, 2019, 45, 41-57.	1.8	12
592	Review: Modelling the pathology and behaviour of frontotemporal dementia. Neuropathology and Applied Neurobiology, 2019, 45, 58-80.	1.8	13
593	RNA processing in skeletal muscle biology and disease. Transcription, 2019, 10, 1-20.	1.7	28

#	Article	IF	Citations
594	C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathologica, 2019, 137, 487-500.	3.9	94
595	Biomarkers for diseases with TDP-43 pathology. Molecular and Cellular Neurosciences, 2019, 97, 43-59.	1.0	38
596	Antisense Transcription in Loci Associated to Hereditary Neurodegenerative Diseases. Molecular Neurobiology, 2019, 56, 5392-5415.	1.9	29
597	Suppression of the yeast elongation factor Spt4 ortholog reduces expanded SCA36 GGCCUG repeat aggregation and cytotoxicity. Brain Research, 2019, 1711, 29-40.	1.1	17
598	Repeated repeat problems: Combinatorial effect of C9orf72-derived dipeptide repeat proteins. International Journal of Biological Macromolecules, 2019, 127, 136-145.	3.6	13
599	Molecular Mechanisms of Neurodegeneration Related to C9orf72 Hexanucleotide Repeat Expansion. Behavioural Neurology, 2019, 2019, 1-18.	1.1	63
600	RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 469-495.	9.6	32
601	C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathologica, 2019, 137, 1-26.	3.9	53
602	Review: Neuropathology of nonâ€tau frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2019, 45, 19-40.	1.8	93
603	A Chemical Screen Identifies Compounds Limiting the Toxicity of C9ORF72 Dipeptide Repeats. Cell Chemical Biology, 2019, 26, 235-243.e5.	2.5	16
604	Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathologica, 2019, 137, 27-46.	3.9	87
605	The Motor Neuron Diseases and Amyotrophic Lateral Sclerosis. , 2019, , 157-191.		0
606	Multifaceted role of SMCR8 as autophagy regulator. Small GTPases, 2020, 11, 53-61.	0.7	9
607	Small molecule targeting of RNA structures in neurological disorders. Annals of the New York Academy of Sciences, 2020, 1471, 57-71.	1.8	18
608	Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum. Neurobiology of Disease, 2020, 134, 104639.	2.1	101
609	Effects of particle size on the quality attributes of wheat flour made by the milling process. Cereal Chemistry, 2020, 97, 172-182.	1.1	18
610	Poly-glycineâ€“alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathologica, 2020, 139, 99-118.	3.9	49
611	A Pseudo-Blind Convolutional Neural Network for the Reduction of Compression Artifacts. IEEE Transactions on Circuits and Systems for Video Technology, 2020, 30, 1121-1135.	5.6	29

#	Article	IF	Citations
612	A Return to the Origin of the EMGS: Rejuvenating the Quest for Human Germ Cell Mutagens and Determining the Risk to Future Generations. Environmental and Molecular Mutagenesis, 2020, 61, 42-54.	0.9	13
613	The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2Î± in Neurodegeneration. Journal of Neuropathology and Experimental Neurology, 2020, 79, 123-143.	0.9	72
614	Autophagy Induction as a Therapeutic Strategy for Neurodegenerative Diseases. Journal of Molecular Biology, 2020, 432, 2799-2821.	2.0	157
615	Macrophage Migration Inhibitory Factor. Methods in Molecular Biology, 2020, , .	0.4	0
616	Active polyâ€GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Molecular Medicine, 2020, 12, e10919.	3.3	39
617	Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model. Neuron, 2020, 105, 645-662.e11.	3.8	70
618	Three-Dimensional Structure of RNA Monomeric G-Quadruplex Containing ALS and FTD Related G4C2 Repeat and Its Binding with TMPyP4 Probed by Homology Modeling based on Experimental Constraints and Molecular Dynamics Simulations. ACS Chemical Neuroscience, 2020, 11, 57-75.	1.7	13
619	Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease, 2020, 145, 105063.	2.1	23
620	ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron, 2020, 108, 822-842.	3.8	212
621	Absence of Survival and Motor Deficits in 500 Repeat C9ORF72 BAC Mice. Neuron, 2020, 108, 775-783.e4.	3.8	33
622	Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18591-18599.	3.3	79
623	C9orf72-associated SMCR8 protein binds in the ubiquitin pathway and with proteins linked with neurological disease. Acta Neuropathologica Communications, 2020, 8, 110.	2.4	15
624	It Takes Two to Tango: DPRs in ALS and SCA36. Neuron, 2020, 107, 202-204.	3.8	3
625	RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context. Journal of Molecular Biology, 2020, 432, 166699.	2.0	17
626	Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-29.	1.9	77
627	The carboxyl termini of RAN translated GGGGCC nucleotide repeat expansions modulate toxicity in models of ALS/FTD. Acta Neuropathologica Communications, 2020, 8, 122.	2.4	15
628	Metformin treatment of the C9orf72 ALS/FTD mouse: Almost too good for words. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19627-19628.	3.3	2
629	A Crucial Role for the Protein Quality Control System in Motor Neuron Diseases. Frontiers in Aging Neuroscience, 2020, 12, 191.	1.7	16

#	Article	IF	Citations
630	Phase Separation of Toxic Dipeptide Repeat Proteins Related to C9orf72 ALS/FTD. Biophysical Journal, 2020, 119, 843-851.	0.2	26
631	Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease. Frontiers in Neuroscience, 2020, 14, 824.	1.4	48
632	Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. Molecular and Cellular Neurosciences, 2020, 109, 103553.	1.0	19
633	Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat Experimental Model of ALS. , 2020, , .		1
634	RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3. Acta Neuropathologica Communications, 2020, 8, 177.	2.4	17
635	C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Science Translational Medicine, 2020, 12, .	5.8	115
636	Knock in of a hexanucleotide repeat expansion in the C9orf72 gene induces ALS in rats. Animal Models and Experimental Medicine, 2020, 3, 237-244.	1.3	15
637	Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia. Ageing Research Reviews, 2020, 64, 101172.	5.0	5
638	Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Neuroscience Bulletin, 2020, 36, 1057-1070.	1.5	4
639	Phenotypic diversity in ALS and the role of poly-conformational protein misfolding. Acta Neuropathologica, 2020, 142, 41-55.	3.9	9
640	RNA Metabolism and Therapeutics in Amyotrophic Lateral Sclerosis. , 2020, , .		1
641	Co-expression of C9orf72 related dipeptide-repeats over 1000 repeat units reveals age- and combination-specific phenotypic profiles in Drosophila. Acta Neuropathologica Communications, 2020, 8, 158.	2.4	23
642	Nuclear Import Receptors Directly Bind to Arginine-Rich Dipeptide Repeat Proteins and Suppress Their Pathological Interactions. Cell Reports, 2020, 33, 108538.	2.9	69
643	C9orf72 Hexanucleotide Repeat in Huntington-Like Patients: Systematic Review and Meta-Analysis. Frontiers in Genetics, 2020, 11, 551780.	1.1	4
644	Soluble and insoluble dipeptide repeat protein measurements in C9orf72-frontotemporal dementia brains show regional differential solubility and correlation of poly-GR with clinical severity. Acta Neuropathologica Communications, 2020, 8, 184.	2.4	25
645	C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature, 2020, 582, 89-94.	13.7	182
646	Expansion of GGC Repeat in GIPC1 Is Associated with Oculopharyngodistal Myopathy. American Journal of Human Genetics, 2020, 106, 793-804.	2.6	90
647	Hexanucleotide Repeat Expansions in c9FTD/ALS and SCA36 Confer Selective Patterns of Neurodegeneration InÂVivo. Cell Reports, 2020, 31, 107616.	2.9	37

#	Article	IF	Citations
648	Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS. Neuroscience Bulletin, 2020, 36, 1414-1428.	1.5	10
649	Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. Human Molecular Genetics, 2020, 29, 2200-2217.	1.4	39
650	Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD. Molecular Neurodegeneration, 2020, 15, 34.	4.4	32
651	Congenic expression of poly-GA but not poly-PR in mice triggers selective neuron loss and interferon responses found in C9orf72 ALS. Acta Neuropathologica, 2020, 140, 121-142.	3.9	44
652	Chaperone-Mediated Protein Disaggregation Triggers Proteolytic Clearance of Intra-nuclear Protein Inclusions. Cell Reports, 2020, 31, 107680.	2.9	43
653	Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2020, 21, 4291.	1.8	27
654	Biological phase separation: cell biology meets biophysics. Biophysical Reviews, 2020, 12, 519-539.	1.5	125
655	A widespread family of heat-resistant obscure (Hero) proteins protect against protein instability and aggregation. PLoS Biology, 2020, 18, e3000632.	2.6	51
656	Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases. Journal of Molecular Biology, 2020, 432, 2714-2734.	2.0	46
657	Cellâ€toâ€cell transmission of C9orf72 polyâ€(Glyâ€Ala) triggers key features of <scp>ALS</scp> / <scp>FTD</scp>. EMBO Journal, 2020, 39, e102811.	3.5	51
658	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nature Reviews Neurology, 2020, 16, 213-228.	4.9	73
659	Omics Approach to Axonal Dysfunction of Motor Neurons in Amyotrophic Lateral Sclerosis (ALS). Frontiers in Neuroscience, 2020, 14, 194.	1.4	42
660	Non-AUG start codons: Expanding and regulating the small and alternative ORFeome. Experimental Cell Research, 2020, 391, 111973.	1.2	49
661	Generation of a human induced pluripotent stem cell (iPSC) line (IBMS-iPSC-048-05) from a patient with ALS and parkinsonism having a hexanucleotide repeat expansion mutation in C9orf72 gene. Stem Cell Research, 2020, 44, 101734.	0.3	0
662	Functional Roles of Long Non-coding RNAs in Motor Neuron Development and Disease. Journal of Biomedical Science, 2020, 27, 38.	2.6	27
663	ALS, a cellular whodunit on motor neuron degeneration. Molecular and Cellular Neurosciences, 2020, 107, 103524.	1.0	9
664	A Functional Non-coding RNA Is Produced from xbp-1 mRNA. Neuron, 2020, 107, 854-863.e6.	3.8	10
665	The pathophysiology of neurodegenerative disease: Disturbing the balance between phase separation and irreversible aggregation. Progress in Molecular Biology and Translational Science, 2020, 174, 187-223.	0.9	16

#	Article	IF	Citations
666	C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression. Nature Communications, 2020, 11, 3354.	5.8	43
668	A synthetic Pur-based peptide binds and alters G-quadruplex secondary structure present in the expanded RNA repeat of C9orf72 ALS/FTD. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118674.	1.9	8
669	Lack of RAN-mediated toxicity in Huntingtonâ€™s disease knock-in mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4411-4417.	3.3	24
670	Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. International Journal of Molecular Sciences, 2020, 21, 1115.	1.8	70
671	Localization elements and zip codes in the intracellular transport and localization of messenger RNAs in Saccharomyces cerevisiae. Wiley Interdisciplinary Reviews RNA, 2020, 11, e1591.	3.2	11
672	Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Molecular Neurodegeneration, 2020, 15, 13.	4.4	58
673	C9orf72 associates with inactive Rag GTPases and regulates mTORC1â€mediated autophagosomal and lysosomal biogenesis. Aging Cell, 2020, 19, e13126.	3.0	34
674	Short Tandem Repeat-Enriched Architectural RNAs in Nuclear Bodies: Functions and Associated Diseases. Non-coding RNA, 2020, 6, 6.	1.3	25
675	Nucleocytoplasmic Proteomic Analysis Uncovers eRF1 and Nonsense-Mediated Decay as Modifiers of ALS/FTD C9orf72 Toxicity. Neuron, 2020, 106, 90-107.e13.	3.8	58
676	On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability. Journal of Biological Chemistry, 2020, 295, 4134-4170.	1.6	178
677	A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a senescence-associated secretory phenotype. Neurobiology of Aging, 2020, 90, 125-134.	1.5	11
678	Arginine in C9ORF72 Dipolypeptides Mediates Promiscuous Proteome Binding and Multiple Modes of Toxicity. Molecular and Cellular Proteomics, 2020, 19, 640-654.	2.5	31
679	Pathomechanism Heterogeneity in the Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disease Spectrum: Providing Focus Through the Lens of Autophagy. Journal of Molecular Biology, 2020, 432, 2692-2713.	2.0	18
680	Reduced autophagy upon C9ORF72 loss synergizes with dipeptide repeat protein toxicity in G4C2 repeat expansion disorders. EMBO Journal, 2020, 39, e100574.	3.5	100
681	Glial Cellsâ€”The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine, 2020, 9, 261.	1.0	51
683	Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Molecular Neurodegeneration, 2020, 15, 7.	4.4	34
684	CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescues neurodegeneration. Acta Neuropathologica, 2020, 140, 81-84.	3.9	24
685	Recognition of expanded GGGGCC hexanucleotide repeat by synthetic ligand through interhelical binding. Biochemical and Biophysical Research Communications, 2020, 531, 56-61.	1.0	3

#	Article	IF	Citations
686	Small heat shock proteins in neurodegenerative diseases. Cell Stress and Chaperones, 2020, 25, 679-699.	1.2	57
687	Dipeptide repeat derived from C9orf72 hexanucleotide expansions forms amyloids or natively unfolded structures inÂvitro. Biochemical and Biophysical Research Communications, 2020, 526, 410-416.	1.0	7
688	Ablation of C9orf72 together with excitotoxicity induces ALS in rats. FEBS Journal, 2021, 288, 1712-1723.	2.2	15
689	TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease. Progress in Retinal and Eye Research, 2021, 81, 100883.	7.3	40
690	RAB39B's role in membrane traffic, autophagy, and associated neuropathology. Journal of Cellular Physiology, 2021, 236, 1579-1592.	2.0	16
691	Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. British Journal of Pharmacology, 2021, 178, 1353-1372.	2.7	20
692	Nuclear Envelope and Nuclear Pore Complexes in Neurodegenerative Diseasesâ€"New Perspectives for Therapeutic Interventions. Molecular Neurobiology, 2021, 58, 983-995.	1.9	16
693	Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology, 2021, 61, 831-852.	4.2	54
694	Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration. Neurobiology of Disease, 2021, 149, 105225.	2.1	54
695	Coâ€incidental C9orf72 expansion mutationâ€related frontotemporal lobar degeneration pathology and sporadic Creutzfeldtâ^'Jakob disease. European Journal of Neurology, 2021, 28, 1009-1015.	1.7	2
696	Unfolded protein response activation in C9orf72 frontotemporal dementia is associated with dipeptide pathology and granulovacuolar degeneration in granule cells. Brain Pathology, 2021, 31, 163-173.	2.1	18
697	Translational control in aging and neurodegeneration. Wiley Interdisciplinary Reviews RNA, 2021, 12, e1628.	3.2	17
698	Long nonâ€coding RNAs in motor neuron development and disease. Journal of Neurochemistry, 2021, 156, 777-801.	2.1	22
699	Role and therapeutic potential of liquidâ€"liquid phase separation in amyotrophic lateral sclerosis. Journal of Molecular Cell Biology, 2021, 13, 15-28.	1.5	23
701	Mitophagy Modulation, a New Player in the Race against ALS. International Journal of Molecular Sciences, 2021, 22, 740.	1.8	25
702	Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Cells, 2021, 10, 249.	1.8	16
703	Molecular conformations and dynamics of nucleotide repeats associated with neurodegenerative diseases: double helices and CAG hairpin loops. Computational and Structural Biotechnology Journal, 2021, 19, 2819-2832.	1.9	11
704	Correlation between C9ORF72 mutation and neurodegenerative diseases: A comprehensive review of the literature. International Journal of Medical Sciences, 2021, 18, 378-386.	1.1	10

#	Article	IF	Citations
705	Amyotrophic Lateral Sclerosis Genes in Drosophila melanogaster. International Journal of Molecular Sciences, 2021, 22, 904.	1.8	16
706	Molecular Dynamics Study of Structure, Folding, and Aggregation of Poly-PR and Poly-GR Proteins. Biophysical Journal, 2021, 120, 64-72.	0.2	8
707	Failure to Degrade CAT-Tailed Proteins Disrupts Neuronal Morphogenesis and Cell Survival. Cell Reports, 2021, 34, 108599.	2.9	33
708	RNA-Mediated Metabolic Defects in Microsatellite Expansion Diseases. , 2021, , 153-178.		0
709	Inducible expression of human C9ORF72 36Ã— G4C2 hexanucleotide repeats is sufficient to cause RAN translation and rapid muscular atrophy in mice. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	11
711	SFPQ regulates the accumulation of RNA foci and dipeptide repeat proteins from the expanded repeat mutation in C9orf72. Journal of Cell Science, 2021, 134, .	1.2	5
713	Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nature Communications, 2021, 12, 847.	5.8	48
714	C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy, 2021, 17, 3306-3322.	4.3	52
715	p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell, 2021, 184, 689-708.e20.	13.5	104
716	Emerging Perspectives on Dipeptide Repeat Proteins in C9ORF72 ALS/FTD. Frontiers in Cellular Neuroscience, 2021, 15, 637548.	1.8	29
717	Dissolving the Complex Role Aggregation Plays in Neurodegenerative Disease. Movement Disorders, 2021, 36, 1061-1069.	2.2	9
718	Duplexes Formed by G₄C₂ Repeats Contain Alternate Slow- and Fast-Flipping GÂ·G Base Pairs. Biochemistry, 2021, 60, 1097-1107.	1.2	5
720	C9orf72 regulates energy homeostasis by stabilizing mitochondrial complex I assembly. Cell Metabolism, 2021, 33, 531-546.e9.	7.2	70
721	The progress inC9orf72research: ALS/FTD pathogenesis, functions and structure. Small GTPases, 2022, 13, 56-76.	0.7	6
722	G-Quadruplexes as pathogenic drivers in neurodegenerative disorders. Nucleic Acids Research, 2021, 49, 4816-4830.	6.5	76
723	Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nature Reviews Neuroscience, 2021, 22, 197-208.	4.9	107
724	Mitochondrial Fission Protein 1: Emerging Roles in Organellar Form and Function in Health and Disease. Frontiers in Endocrinology, 2021, 12, 660095.	1.5	59
725	BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model. Clinical Epigenetics, 2021, 13, 56.	1.8	5

#	Article	IF	Citations
726	Hypothesis and Theory: Roles of Arginine Methylation in C9orf72-Mediated ALS and FTD. Frontiers in Cellular Neuroscience, 2021, 15, 633668.	1.8	8
727	Downregulation of TOP2 modulates neurodegeneration caused by GGGGCC expanded repeats. Human Molecular Genetics, 2021, 30, 893-901.	1.4	4
728	Multiple ways to a dead end: diverse mechanisms by which ALS mutant genes induce cell death. Cell Cycle, 2021, 20, 631-646.	1.3	3
729	Systematically defining selective autophagy receptor-specific cargo using autophagosome content profiling. Molecular Cell, 2021, 81, 1337-1354.e8.	4.5	73
730	Mechanisms of repeat-associated non-AUG translation in neurological microsatellite expansion disorders. Biochemical Society Transactions, 2021, 49, 775-792.	1.6	12
731	UPF1 reduces C9orf72 HRE-induced neurotoxicity in the absence of nonsense-mediated decay dysfunction. Cell Reports, 2021, 34, 108925.	2.9	14
733	The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Proteostasis Factors. Journal of Neuropathology and Experimental Neurology, 2021, 80, 494-513.	0.9	4
734	Combating deleterious phase transitions in neurodegenerative disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118984.	1.9	52
735	The alternative initiation factor eIF2A plays key role in RAN translation of myotonic dystrophy type 2 CCUGâ€¢CAGG repeats. Human Molecular Genetics, 2021, 30, 1020-1029.	1.4	17
737	CaBagE: A Cas9-based Background Elimination strategy for targeted, long-read DNA sequencing. PLoS ONE, 2021, 16, e0241253.	1.1	17
738	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
739	Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. International Journal of Molecular Sciences, 2021, 22, 3843.	1.8	16
740	Karyopherin abnormalities in neurodegenerative proteinopathies. Brain, 2021, 144, 2915-2932.	3.7	20
741	Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD. Biomedicines, 2021, 9, 601.	1.4	7
742	Keeping the balance: The noncoding RNA 7SK as a master regulator for neuron development and function. BioEssays, 2021, 43, e2100092.	1.2	5
743	30 years of repeat expansion disorders: What have we learned and what are the remaining challenges?. American Journal of Human Genetics, 2021, 108, 764-785.	2.6	170
744	Retinal Damage in Amyotrophic Lateral Sclerosis: Underlying Mechanisms. Eye and Brain, 2021, Volume 13, 131-146.	3.8	14
745	C9ORF72: What It Is, What It Does, and Why It Matters. Frontiers in Cellular Neuroscience, 2021, 15, 661447.	1.8	61

#	Article	IF	Citations
746	New advances in Amyotrophic Lateral Sclerosis genetics: Towards gene therapy opportunities for familial and young cases. Revue Neurologique, 2021, 177, 524-535.	0.6	3
747	Widespread displacement of DNAâ€•and RNAâ€binding factors underlies toxicity of arginineâ€rich cellâ€penetrating peptides. EMBO Journal, 2021, 40, e103311.	3.5	21
748	The role of amyloid oligomers in neurodegenerative pathologies. International Journal of Biological Macromolecules, 2021, 181, 582-604.	3.6	38
749	Molecular mechanisms underlying nucleotide repeat expansion disorders. Nature Reviews Molecular Cell Biology, 2021, 22, 589-607.	16.1	151
750	Proline/arginine dipeptide repeat polymers derail protein folding in amyotrophic lateral sclerosis. Nature Communications, 2021, 12, 3396.	5.8	14
751	Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence. Human Molecular Genetics, 2021, 30, 1797-1810.	1.4	6
752	Stress Granules and Neurodegenerative Disorders: A Scoping Review. Frontiers in Aging Neuroscience, 2021, 13, 650740.	1.7	22
753	Expression of C9orf72 hexanucleotide repeat expansion leads to formation of RNA foci and dipeptide repeat proteins but does not influence autophagy or proteasomal function in neuronal cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119021.	1.9	5
754	Multiple pathways of toxicity induced by C9orf72 dipeptide repeat aggregates and G4C2 RNA in a cellular model. ELife, 2021, 10, .	2.8	17
755	Axonal Transport and Local Translation of mRNA in Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2021, 14, 697973.	1.4	15
756	Synthetic hydrogel mimics of the nuclear pore complex for the study of nucleocytoplasmic transport defects in C9orf72 ALS/FTD. Analytical and Bioanalytical Chemistry, 2022, 414, 525-532.	1.9	3
757	UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron, 2021, 109, 1949-1962.e6.	3.8	24
758	Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion. Frontiers in Cellular Neuroscience, 2021, 15, 660693.	1.8	9
759	Immunotherapies for Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 654739.	1.1	31
760	The Skeletal Muscle Emerges as a New Disease Target in Amyotrophic Lateral Sclerosis. Journal of Personalized Medicine, 2021, 11, 671.	1.1	20
761	Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers. Cellular and Molecular Life Sciences, 2021, 78, 6143-6160.	2.4	23
762	Structure of the human C9orf72-SMCR8 complex reveals a multivalent protein interaction architecture. PLoS Biology, 2021, 19, e3001344.	2.6	6
763	Human oncoprotein 5MP suppresses general and repeat-associated non-AUG translation via eIF3 by a common mechanism. Cell Reports, 2021, 36, 109376.	2.9	16

#	Article	IF	Citations
764	Humoral response to neurofilaments and dipeptide repeats in ALS progression. Annals of Clinical and Translational Neurology, 2021, 8, 1831-1844.	1.7	8
765	Amyotrophic Lateral Sclerosis (ALS): Stressed by Dysfunctional Mitochondria-Endoplasmic Reticulum Contacts (MERCs). Cells, 2021, 10, 1789.	1.8	23
766	Nuclear speckles: dynamic hubs of gene expression regulation. FEBS Journal, 2022, 289, 7234-7245.	2.2	50
767	Nanoscopic investigation of C9orf72 poly-GA oligomers on nuclear membrane disruption by a photoinducible platform. Communications Chemistry, 2021, 4, .	2.0	2
768	There and Back Again: Hox Clusters Use Both DNA Strands. Journal of Developmental Biology, 2021, 9, 28.	0.9	3
769	FTLD Patientâ€“Derived Fibroblasts Show Defective Mitochondrial Function and Accumulation of p62. Molecular Neurobiology, 2021, 58, 5438-5458.	1.9	4
771	Early Divergence in Misfolding Pathways of Amyloidâ€Beta Peptides. ChemPhysChem, 2021, 22, 2158-2163.	1.0	4
772	Nuclear export and translation of circular repeat-containing intronic RNA in C9ORF72-ALS/FTD. Nature Communications, 2021, 12, 4908.	5.8	41
773	Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. Current Opinion in Neurology, 2021, Publish Ahead of Print, .	1.8	12
774	Long Non-coding RNAs in Pathogenesis of Neurodegenerative Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 719247.	1.8	21
776	Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis. Cells, 2021, 10, 2247.	1.8	17
777	Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease. Journal of Molecular Biology, 2022, 434, 167220.	2.0	13
778	Measuring and Interpreting Nuclear Transport in Neurodegenerative Diseaseâ€”The Example of C9orf72 ALS. International Journal of Molecular Sciences, 2021, 22, 9217.	1.8	8
779	Translation of the poly(GR) frame in C9ORF72-ALS/FTD is regulated by cis-elements involved in alternative splicing. Neurobiology of Aging, 2021, 105, 327-332.	1.5	10
780	ZNF598 co-translationally titrates poly(GR) protein implicated in the pathogenesis of C9ORF72-associated ALS/FTD. Nucleic Acids Research, 2021, 49, 11294-11311.	6.5	21
781	RNA Deregulation in Amyotrophic Lateral Sclerosis: The Noncoding Perspective. International Journal of Molecular Sciences, 2021, 22, 10285.	1.8	18
782	Translational control of polyamine metabolism by CNBP is required for Drosophila locomotor function. ELife, 2021, 10, .	2.8	10
783	Phase separation and toxicity of C9orf72 poly(PR) depends on alternate distribution of arginine. Journal of Cell Biology, 2021, 220, .	2.3	21

#	Article	IF	Citations
784	Elucidating the Role of Cerebellar Synaptic Dysfunction in C9orf72-ALS/FTD â€" a Systematic Review and Meta-Analysis. Cerebellum, 2022, 21, 681-714.	1.4	3
785	Interactome screening ofC9orf72dipeptide repeats reveals VCP sequestration and functional impairment by polyGA. Brain, 2022, 145, 684-699.	3.7	15
786	SRSF protein kinase 1 modulates RAN translation and suppresses CGG repeat toxicity. EMBO Molecular Medicine, 2021, 13, e14163.	3.3	17
787	The porphyrin TMPyP4 inhibits elongation during the noncanonical translation of the FTLD/ALS-associated GGGGCC repeat in the C9orf72 gene. Journal of Biological Chemistry, 2021, 297, 101120.	1.6	17
788	NEAT1 lncRNA and amyotrophic lateral sclerosis. Neurochemistry International, 2021, 150, 105175.	1.9	12
789	Fluid Biomarkers of Frontotemporal Lobar Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 123-139.	0.8	7
790	Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy. , 2021, , 19-47.		0
791	Ca2+ dysregulation in the pathogenesis of amyotrophic lateral sclerosis. International Review of Cell and Molecular Biology, 2021, 363, 21-47.	1.6	6
792	Small molecule targeting r(UGGAA)n disrupts RNA foci and alleviates disease phenotype in Drosophila model. Nature Communications, 2021, 12, 236.	5.8	39
793	RNA-Binding Protein Misregulation in Microsatellite Expansion Disorders. Advances in Experimental Medicine and Biology, 2014, 825, 353-388.	0.8	27
794	Purification of Antibodies Against Entamoeba histolytica MIF and Their Use in Analyzing Human and Mouse Samples. Methods in Molecular Biology, 2020, 2080, 237-247.	0.4	3
795	RNA Granules and Their Role in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, 1203, 195-245.	0.8	19
796	Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders. Molecular Neurobiology, 2017, 54, 4466-4476.	1.9	30
797	Neurodegenerative Diseases and RNA-Mediated Toxicity. , 2018, , 441-475.		4
798	Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36. Neuron, 2020, 107, 292-305.e6.	3.8	51
799	The role of DNA damage response in amyotrophic lateral sclerosis. Essays in Biochemistry, 2020, 64, 847-861.	2.1	33
800	Therapeuticsâ€"how to treat phase separation-associated diseases. Emerging Topics in Life Sciences, 2020, 4, 331-342.	1.1	65
801	Antibodies against the mono-methylated arginine-glycine repeat (MMA-RG) of the Epsteinâ€"Barr virus nuclear antigen 2 (EBNA2) identify potential cellular proteins targeted in viral transformation. Journal of General Virology, 2017, 98, 2128-2142.	1.3	8

#	Article	IF	Citations
812	Recent advances in understanding frontotemporal degeneration. F1000Research, 2019, 8, 2098.	0.8	16
813	Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies. Faculty Reviews, 2020, 9, 12.	1.7	17
814	LSM12-EPAC1 defines a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient. PLoS Biology, 2020, 18, e3001002.	2.6	12
815	Protein Interaction Analysis of Senataxin and the ALS4 L389S Mutant Yields Insights into Senataxin Post-Translational Modification and Uncovers Mutant-Specific Binding with a Brain Cytoplasmic RNA-Encoded Peptide. PLoS ONE, 2013, 8, e78837.	1.1	17
816	Repeat Associated Non-AUG Translation (RAN Translation) Dependent on Sequence Downstream of the ATXN2 CAG Repeat. PLoS ONE, 2015, 10, e0128769.	1.1	37
817	Distinct C9orf72-Associated Dipeptide Repeat Structures Correlate with Neuronal Toxicity. PLoS ONE, 2016, 11, e0165084.	1.1	39
818	The Proline/Arginine Dipeptide from Hexanucleotide Repeat ExpandedC9ORF72Inhibits the Proteasome. ENeuro, 2017, 4, ENEURO.0249-16.2017.	0.9	62
819	The <scp>RNA</scp> exosome complex degrades expanded hexanucleotide repeat <scp>RNA</scp> in C9orf72 <scp>FTLD</scp> / <scp>ALS</scp>. EMBO Journal, 2020, 39, e102700.	3.5	18
820	Preclinical progression of neurodegenerative diseases. Nagoya Journal of Medical Science, 2018, 80, 289-298.	0.6	32
821	tRNA-Derived Small RNAs: The Good, the Bad and the Ugly. Med One, 2019, , .	1.5	3
822	Proteomics and C9orf72 neuropathology identify ribosomes as poly-GR/PR interactors driving toxicity. Life Science Alliance, 2018, 1, e201800070.	1.3	88
823	Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity. Frontiers in Pharmacology, 2020, 11, 569661.	1.6	10
824	Mislocalization, aggregation formation and defect in proteolysis in ALS. AIMS Molecular Science, 2016, 3, 246-268.	0.3	2
825	The 5â€™-Untranslated Region of the C9orf72 mRNA Exhibits a Phylogenetic Alignment to the Cis-Aconitase Iron-Responsive Element; Novel Therapies for Amytrophic Lateral Sclerosis. Neuroscience and Medicine, 2016, 07, 15-26.	0.2	8
826	Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells. World Journal of Stem Cells, 2015, 7, 823.	1.3	8
827	Advances and challenges in understanding the multifaceted pathogenesis of amyotrophic lateral sclerosis. Swiss Medical Weekly, 2015, 145, w14054.	0.8	21
828	GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. ELife, 2015, 4, e08881.	2.8	81
829	Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. ELife, 2015, 4, .	2.8	38

#	Article	IF	Citations
830	Structural basis of nucleic-acid recognition and double-strand unwinding by the essential neuronal protein Pur-alpha. ELife, 2016, 5, .	2.8	35
831	The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. ELife, 2016, 5, .	2.8	228
832	Suppression of C9orf72 RNA repeat-induced neurotoxicity by the ALS-associated RNA-binding protein Zfp106. ELife, 2017, 6, .	2.8	44
833	TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. ELife, 2020, 9, .	2.8	48
834	C9orf72, a protein associated with amyotrophic lateral sclerosis (ALS) is a guanine nucleotide exchange factor. PeerJ, 2018, 6, e5815.	0.9	45
837	Reduction of oxidative stress suppresses poly-GR-mediated toxicity in zebrafish embryos. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	5
839	Modeling C9orf72-Related Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Drosophila. Frontiers in Cellular Neuroscience, 2021, 15, 770937.	1.8	4
840	CCGâ€¢CGG interruptions in highâ€penetrance SCA8 families increase RAN translation and protein toxicity. EMBO Molecular Medicine, 2021, 13, e14095.	3.3	12
841	A C. elegans model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation. Nature Communications, 2021, 12, 6025.	5.8	27
842	Protein clearance strategies for disease intervention. Journal of Neural Transmission, 2022, 129, 141-172.	1.4	15
843	Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes. , 2014, , 93-109.		0
844	Hexanucleotide Repeat Expansion in C9ORF72 Is Not Detected in the Treatment-Resistant Schizophrenia Patients of Chinese Han. PLoS ONE, 2015, 10, e0145347.	1.1	0
845	Antisense Oligonucleotides for Amyotrophic Lateral Sclerosis. , 2016, , 99-109.		0
847	Amyotrophic Lateral Sclerosis and Other TDP-43 Proteinopathies. , 2018, , 99-115.		0
860	Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis. Annals of Neurology, 2022, 91, 13-20.	2.8	11
861	Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G ₄ C ₂) Tj ETQq1 1 0.784314 rgBT	5.8	39
862	Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice. Human Molecular Genetics, 2021, 29, 3900-3918.	1.4	7
863	Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion. Methods in Molecular Biology, 2020, 2176, 185-208.	0.4	1

#	Article	IF	Citations
864	Motoneuronerkrankungen. , 2020, , 153-177.		0
865	Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration. Bio-protocol, 2020, 10, e3659.	0.2	2
868	Proteostasis deregulation as a driver of C9ORF72 pathogenesis. Journal of Neurochemistry, 2021, 159, 941.	2.1	2
873	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. , 2014, , 209-248.		3
874	Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. American Journal of Neurodegenerative Disease, 2013, 2, 145-75.	0.1	116
875	C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. American Journal of Neurodegenerative Disease, 2014, 3, 1-18.	0.1	21
876	Advances in Proteasome Enhancement by Small Molecules. Biomolecules, 2021, 11, 1789.	1.8	13
877	Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 12236.	1.8	40
878	Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degenerationâ€"Insights into disease mechanisms and current therapeutic approaches. Molecular Psychiatry, 2022, 27, 1300-1309.	4.1	17
879	Epigenetic Small Molecules Rescue Nucleocytoplasmic Transport and DNA Damage Phenotypes in C9ORF72 ALS/FTD. Brain Sciences, 2021, 11, 1543.	1.1	5
880	CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders. Molecular Neurobiology, 2022, 59, 968-982.	1.9	19
881	Ribosome profiling reveals novel regulation of C9ORF72 GGGGCC repeat-containing RNA translation. Rna, 2022, 28, 123-138.	1.6	17
882	C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation. EMBO Journal, 2022, 41, e105026.	3.5	13
883	Characterization of RAN Translation and Antisense Transcription in Primary Cell Cultures of Patients with Myotonic Dystrophy Type 1. Journal of Clinical Medicine, 2021, 10, 5520.	1.0	7
884	Metals in ALS TDP-43 Pathology. International Journal of Molecular Sciences, 2021, 22, 12193.	1.8	13
885	Aggregation and the Intrinsic Structural Disorder of Dipeptide Repeat Peptides of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Characterized by NMR. Journal of Physical Chemistry B, 2021, 125, 12446-12456.	1.2	2
886	A rare case of frontotemporal dementia with amyotrophic lateral sclerosis. Archives of Mental Health, 2021, 22, 162.	0.1	0
887	RAN proteins in neurodegenerative disease: Repeating themes and unifying therapeutic strategies. Current Opinion in Neurobiology, 2022, 72, 160-170.	2.0	10

#	Article	IF	Citations
888	Pathological phase transitions in ALS-FTD impair dynamic RNAâ€“protein granules. Rna, 2022, 28, 97-113.	1.6	15
889	Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. Neurochemical Journal, 2021, 15, 339-352.	0.2	1
890	A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis. Clinical and Translational Medicine, 2022, 12, e657.	1.7	2
892	HDAC6 Interacts With Poly (GA) and Modulates its Accumulation in c9FTD/ALS. Frontiers in Cell and Developmental Biology, 2021, 9, 809942.	1.8	4
893	Possibilities and challenges of small molecule organic compounds for the treatment of repeat diseases. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2022, 98, 30-48.	1.6	8
894	Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurological Research and Practice, 2022, 4, 2.	1.0	27
895	Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends in Neurosciences, 2022, 45, 184-199.	4.2	54
896	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	1.1	6
898	Order controls disordered droplets: structure-function relationships in C9ORF72-derived poly(PR). American Journal of Physiology - Cell Physiology, 2022, 322, C197-C204.	2.1	0
899	Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS. Nucleic Acids Research, 2022, 50, 5401-5423.	6.5	22
900	Non-canonical initiation factors modulate repeat-associated non-AUG translation. Human Molecular Genetics, 2022, 31, 2521-2534.	1.4	19
901	Cortical Hyperexcitability in the Driverâ€™s Seat in ALS. Clinical and Translational Neuroscience, 2022, 6, 5.	0.4	4
902	Endoplasmic reticulumâ€“mitochondria signaling in neurons and neurodegenerative diseases. Journal of Cell Science, 2022, 135, .	1.2	43
903	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
904	Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nature Medicine, 2022, 28, 117-124.	15.2	72
906	Measuring Repeat-Associated Non-AUG (RAN) Translation. Methods in Molecular Biology, 2022, 2428, 113-132.	0.4	0
907	Partners in crime: Proteins implicated in <scp>RNA</scp> repeat expansion diseases. Wiley Interdisciplinary Reviews RNA, 2022, 13, e1709.	3.2	8
908	Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation. Acta Neuropathologica Communications, 2022, 10, 22.	2.4	22

#	Article	IF	Citations
909	Frontotemporal Dementia and Glucose Metabolism. Frontiers in Neuroscience, 2022, 16, 812222.	1.4	10
910	C9orf72 dipeptides disrupt the nucleocytoplasmic transport machinery and cause TDP-43 mislocalisation to the cytoplasm. Scientific Reports, 2022, 12, 4799.	1.6	19
911	Spinocerebellar Ataxia 36: From Mutations Toward Therapies. Frontiers in Genetics, 2022, 13, 837690.	1.1	2
912	Poly-dipeptides produced from C9orf72 hexanucleotide repeats cause selective motor neuron hyperexcitability in ALS. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113813119.	3.3	8
913	Modelling amyotrophic lateral sclerosis in rodents. Nature Reviews Neuroscience, 2022, 23, 231-251.	4.9	17
914	Drosophila as a Model of Unconventional Translation in Spinocerebellar Ataxia Type 3. Cells, 2022, 11, 1223.	1.8	11
915	A mouse model with widespread expression of the C9orf72-linked glycineâ€“arginine dipeptide displays non-lethal ALS/FTD-like phenotypes. Scientific Reports, 2022, 12, 5644.	1.6	9
916	Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo. Scientific Reports, 2022, 12, 5672.	1.6	13
917	Circular RNAs: Emblematic Players of Neurogenesis and Neurodegeneration. International Journal of Molecular Sciences, 2022, 23, 4134.	1.8	19
918	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases. Neurochemistry International, 2022, 155, 105307.	1.9	5
919	Immune Signaling Kinases in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). International Journal of Molecular Sciences, 2021, 22, 13280.	1.8	10
921	The molecular pathogenesis of repeat expansion diseases. Biochemical Society Transactions, 2022, 50, 119-134.	1.6	11
922	Emerging Mechanisms Underpinning Neurophysiological Impairments in C9ORF72 Repeat Expansion-Mediated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Frontiers in Cellular Neuroscience, 2021, 15, 784833.	1.8	4
924	Multifaceted targeted protein degradation systems for different cellular compartments. BioEssays, 2022, 44, e2200008.	1.2	2
933	Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?. Histology and Histopathology, 2021, , 18404.	0.5	2
935	Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers. Clinical and Translational Medicine, 2022, 12, e818.	1.7	11
936	C9orf72 Hexanucleotide Repeat Expansion-Related Neuropathology Is Attenuated by Nasal Rifampicin in Mice. Biomedicines, 2022, 10, 1080.	1.4	2
937	RNA Helicases in Microsatellite Repeat Expansion Disorders and Neurodegeneration. Frontiers in Genetics, 2022, 13, .	1.1	3

#	Article	IF	Citations
939	Biological basis and psychiatric symptoms in frontotemporal dementia. Psychiatry and Clinical Neurosciences, 2022, 76, 351-360.	1.0	5
940	Advances in Treatment of Frontotemporal Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 316-327.	0.9	9
941	C9ORF72-derived poly-GA DPRs undergo endocytic uptake in iAstrocytes and spread to motor neurons. Life Science Alliance, 2022, 5, e202101276.	1.3	6
942	Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. Nature Communications, 2022, 13, 2799.	5.8	28
943	Ribosome inhibition by C9ORF72-ALS/FTD-associated poly-PR and poly-GR proteins revealed by cryo-EM. Nature Communications, 2022, 13, 2776.	5.8	37
944	Expanding Clinical Spectrum of C9ORF72 -Related Disorders and Promising Therapeutic Strategies. Neurology: Genetics, 2022, 8, .	0.9	13
945	Recent Advances in Frontotemporal Dementia. Canadian Journal of Neurological Sciences, 2023, 50, 485-494.	0.3	2
947	Phase Regulation of RNA Binding Protein. Nihon Kessho Gakkaishi, 2022, 64, 140-147.	0.0	0
949	Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics, 2022, 19, 1145-1158.	2.1	26
950	Proteostasis impairment and ALS. Progress in Biophysics and Molecular Biology, 2022, 174, 3-27.	1.4	7
951	Drug screen in iPSC-Neurons identifies nucleoside analogs as inhibitors of (G4C2)n expression in C9orf72 ALS/FTD. Cell Reports, 2022, 39, 110913.	2.9	7
952	NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. Nature Communications, 2022, 13, .	5.8	26
953	Myelin loss in C9orf72 hexanucleotide expansion carriers. Journal of Neuroscience Research, 2022, 100, 1862-1875.	1.3	4
954	Regulating Phase Transition in Neurodegenerative Diseases by Nuclear Import Receptors. Biology, 2022, 11, 1009.	1.3	4
955	Hyperactivity of Purkinje cell and motor deficits in C9orf72 knockout mice. Molecular and Cellular Neurosciences, 2022, 121, 103756.	1.0	5
956	Neuroimmune dysfunction in frontotemporal dementia: Insights from progranulin and C9orf72 deficiency. Current Opinion in Neurobiology, 2022, 76, 102599.	2.0	4
958	Repeat expansion disorders. , 2023, , 293-312.		1
959	Phenotypic mutations contribute to protein diversity and shape protein evolution. Protein Science, 2022, 31, .	3.1	5

#	Article	IF	Citations
960	Approaches to Gene Modulation Therapy for ALS. Neurotherapeutics, 2022, 19, 1159-1179.	2.1	13
961	Sequestration of cellular native factors by biomolecular assemblies: Physiological or pathological?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119360.	1.9	2
962	Basic Concepts and Emergent Disease Mechanisms of Amyotrophic Lateral Sclerosis. , 2023, , 644-665.		1
963	Quality control of cytoplasmic proteins inside the nucleus. Computational and Structural Biotechnology Journal, 2022, 20, 4618-4625.	1.9	3
964	Small Molecules Targeting Repeat Sequences Causing Neurological Disorders. , 2022, , 1-31.		0
965	The contribution of proteasomal impairment to autophagy activation by C9orf72 poly-GA aggregates. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	2
966	Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins. Science Translational Medicine, 2022, 14, .	5.8	9
967	Misfolding at the synapse: A role in amyotrophic lateral sclerosis pathogenesis?. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	0
968	Dipeptide Repeat Pathology in C9orf72-ALS Is Associated with Redox, Mitochondrial and NRF2 Pathway Imbalance. Antioxidants, 2022, 11, 1897.	2.2	8
969	Nucleoporins are degraded via upregulation of ESCRT-III/Vps4 complex in Drosophila models of C9-ALS/FTD. Cell Reports, 2022, 40, 111379.	2.9	10
970	Staufen Impairs Autophagy in Neurodegeneration. Annals of Neurology, 2023, 93, 398-416.	2.8	4
971	Phase separation of low-complexity domains in cellular function and disease. Experimental and Molecular Medicine, 2022, 54, 1412-1422.	3.2	6
972	Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	16
973	Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration. Science, 2022, 378, 94-99.	6.0	32
974	C9orf72 regulates the unfolded protein response and stress granule formation by interacting with eIF2Î±. Theranostics, 2022, 12, 7289-7306.	4.6	6
975	Advances on Cellular Clonotypic Immunity in Amyotrophic Lateral Sclerosis. Brain Sciences, 2022, 12, 1412.	1.1	1
977	Factors predicting disease progression in C9ORF72 ALS patients. Journal of Neurology, 2023, 270, 877-890.	1.8	10
978	CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nature Communications, 2022, 13, .	5.8	18

#	Article	IF	Citations
979	C9orf72 functions in the nucleus to regulate DNA damage repair. Cell Death and Differentiation, 0, , .	5.0	4
982	Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2. International Journal of Molecular Sciences, 2022, 23, 14779.	1.8	4
983	Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	3
984	TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?. International Journal of Molecular Sciences, 2022, 23, 15755.	1.8	7
985	Molecular basis of C9orf72 poly-PR interference with the Î²-karyopherin family of nuclear transport receptors. Scientific Reports, 2022, 12, .	1.6	11
986	How villains are made: The translation of dipeptide repeat proteins in C9ORF72-ALS/FTD. Gene, 2023, 858, 147167.	1.0	6
988	Therapeutic reduction of GGGGCC repeat RNA levels by hnRNPA3 suppresses neurodegeneration in Drosophila models of C9orf72-linked ALS/FTD. Human Molecular Genetics, 2023, 32, 1673-1682.	1.4	7
989	Between Order and Chaos: Understanding the Mechanism and Pathology of RAN Translation. Biological and Pharmaceutical Bulletin, 2023, 46, 139-146.	0.6	0
990	Repeat-associated non-AUG translation in neuromuscular diseases: mechanisms and therapeutic insights. Journal of Biochemistry, 2023, 173, 273-281.	0.9	3
991	The mTORC2/AKT/VCP axis is associated with quality control of the stalled translation of poly(GR) dipeptide repeats in C9-ALS/FTD. Journal of Biological Chemistry, 2023, 299, 102995.	1.6	4
992	FUS regulates RAN translation through modulating the G-quadruplex structure of GGGGCC repeat RNA in C9orf72-linked ALS/FTD. ELife, 0, 12, .	2.8	3
993	Negative regulation of TREM2-mediated C9orf72 poly-GA clearance by the NLRP3 inflammasome. Cell Reports, 2023, 42, 112133.	2.9	7
994	Hallmarks of neurodegenerative diseases. Cell, 2023, 186, 693-714.	13.5	222
995	C9orf72 poly-GA proteins impair neuromuscular transmission. Zoological Research, 2023, 44, 331-340.	0.9	1
996	Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis. Neurotoxicity Research, 0, , .	1.3	2
997	Mammalian telomeric RNA (TERRA) can be translated to produce valineâ€“arginine and glycineâ€“leucine dipeptide repeat proteins. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	20
998	DNA-initiated epigenetic cascades driven by C9orf72 hexanucleotide repeat. Neuron, 2023, 111, 1205-1221.e9.	3.8	6
999	Loss of C9orf72 perturbs the Ran-GTPase gradient and nucleocytoplasmic transport, generating compositionally diverse Importin Î²-1 granules. Cell Reports, 2023, 42, 112134.	2.9	8

#	Article	IF	Citations
1002	Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	4
1003	Messenger RNA Translation Defects in Neurodegenerative Diseases. New England Journal of Medicine, 2023, 388, 1015-1030.	13.9	6
1004	Downregulation of Hsp90 and the antimicrobial peptide Mtk suppresses poly(GR)-induced neurotoxicity in C9ORF72-ALS/FTD. Neuron, 2023, 111, 1381-1390.e6.	3.8	5
1005	Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	5
1006	Clinical and genetic features of amyotrophic lateral sclerosis patients withC9orf72mutations. Brain Communications, 2023, 5, .	1.5	7
1007	Native functions of short tandem repeats. ELife, 0, 12, .	2.8	8
1008	The era of cryptic exons: implications for ALS-FTD. Molecular Neurodegeneration, 2023, 18, .	4.4	19
1009	Disrupted myelin lipid metabolism differentiates frontotemporal dementia caused by GRN and C9orf72 gene mutations. Acta Neuropathologica Communications, 2023, 11, .	2.4	7
1010	Neuronal biomolecular condensates and their implications in neurodegenerative diseases. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
1011	c-Jun N-Terminal Kinase Promotes Stress Granule Assembly and Neurodegeneration in C9orf72-Mediated ALS and FTD. Journal of Neuroscience, 2023, 43, 3186-3197.	1.7	5
1012	Enhanced Degradation of Mutant C9ORF72-Derived Toxic Dipeptide Repeat Proteins by 20S Proteasome Activation Results in Restoration of Proteostasis and Neuroprotection. ACS Chemical Neuroscience, 0, , .	1.7	0
1013	Reduced C9orf72 expression exacerbates polyGR toxicity in patient iPSC-derived motor neurons and a Type I protein arginine methyltransferase inhibitor reduces that toxicity. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	4
1014	C9ORF72 knockdown triggers FTD-like symptoms and cell pathology in mice. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	2
1039	Small Molecules Targeting Repeat Sequences Causing Neurological Disorders. , 2023, , 2107-2137.		0
1043	TDP-43 pathology in the retina of patients with frontotemporal lobar degeneration. Acta Neuropathologica, 0, , .	3.9	0
1072	The molecular basis of translation initiation and its regulation in eukaryotes. Nature Reviews Molecular Cell Biology, 2024, 25, 168-186.	16.1	5
1088	Repeat-associated non-AUG (RAN) translation and Huntington's disease: Pathology, mechanistic and therapeutic perspectives. , 2024, , 187-203.		0